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BACKGROUND AND AIM 
The immune system is an interactive network, including lymphoid organs, cells, 
humoral factors, and cytokines, which works synergistically in host defense from 
pathogens, such as viruses, bacteria, fungi, and parasites, and other foreign molecules.  
The immune system is divided into two parts, named the innate and the adaptive 
immunity, which differ in speed and specificity of response (1). The innate immune 
response is a rapid but non-specific response, which serves as first line of defense 
against many common microorganisms. The innate immune system is composed of 
physical barriers, chemical and microbiological barriers, but it also includes cellular 
components, such as monocytes, macrophages, and neutrophils. However, in the case 
that the innate response fails to eliminate microorganisms and resultant infections, the 
adaptive immune system is activate through the specific cytokines (1, 2). The adaptive 
immune response is a second, more specific, line of defense against pathogens and takes 
several days to even weeks to develop. Compared to the innate response, adaptive 
immunity has immunologic "memory" of pathogenic organisms, involving antigen-
specific recognition. The adaptive immunity involves specialized cells, named B and T 
lymphocytes. B lymphocytes are responsible for humoral immunity, through the 
production of antibodies, while T lymphocytes are involved in the cell-mediated 
immunity. Although the innate and adaptive immune systems have unique functions, 
their components interact and work together to protect the body from infection and 
disease (1, 2). A disruption of this orchestrated process leads immunedeficiencies, 
allergy, autoimmune disease and tumors (3).
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 Primary immunodeficiencies (PIDs) are genetic disorders causing severe defects 
in different components of immune system (4) (Figure 1).  
Figure 1: Genetic defects leading Immunedeficiencies. 
Patients affected with PIDs are highly susceptible to severe and recurrent 
infections and immune reconstituting treatments are only therapeutic approach, which 
ensures these patients a long-term survival (5). Nowadays, more than 200 well 
characterized genetic immunedeficiencies have been identified thanks to the advances in 
molecular genetics and immunology. PIDs are classified according to the component of 
the immune system that is primarily involved, including T, B, natural killer (NK) cells, 
phagocytic cells, and complement proteins. PIDs are often associated with various 
autoimmune manifestations (6). Even though, for a long time autoimmunity and 
immune deficiency have been considered two opposite extremes of immune function, 
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they represent intertwined phenomena that reflect inadequate immune function (7,8). In 
these cases, the autoimmunity does not seem to be related to a defect of tolerance to 
self-antigens, but rather to a persistent stimulation as a result of the inability to eradicate 
foreign antigens (9).  In addition, patients affected with particular forms of PID show an 
increased susceptibility to cancer. In particular, a high cancer susceptibility has been 
reported for some types of PIDs, including ataxia-telangiectasia (AT) and other DNA 
repair deficiencies, common variable immunodeficiency (CVID), Wiskott-Aldrich 
syndrome (WAS), selective IgA deficiency (IgAD), and hyper IgM syndromes (HIGM). 
Within PIDs, the Severe combined immunodeficiency diseases (SCIDs) represent a 
spectrum of illnesses with similar clinical manifestations, which can be divided into 
several categories on the basis of the presence or absence of T cells, B cells and Natural 
Killer (NK) cells.  These are relatively rare diseases, collectively occurring in 1:100.000 
live births. Without immune reconstitution by hematopoietic stem cell transplantation or 
gene therapy, these patients die of infections before 1 year of age. Fortunately, the bone 
marrow transplantation (BMT) HLA-identical donor (RID) is the optimal treatment for 
patients affected with SCIDs (10). To date, more than 20 different genetic defects 
involved in the pathogenesis of SCID in humans have been identified (11, 12). 
Typically, patients with SCID show a severe defect in T-cell differentiation and a direct 
or indirect impairment of B-cell development and function. On the basis of the 
involvement of different cell lines in the pathogenesis of the disease and of the 
subsequent different clinical phenotypes, SCIDs have been till now classified according 
to the presence or absence of T, B, and NK cells (Table 1).  
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SCID form  Phenotype Transmission Gene defect
Pathogenetic 
mechanism
JAK3 deficiency 
-chain  deficiency 
IL-7R  deficiency
T
-
B
+
NK
- 
T
-
B
+
NK
+
AR
JAK 3
c 
IL-7R
Impaired cytokine 
signaling
ADA deficiency 
PNP deficiency
T
-
B
-
NK
- 
T
-
B
+
NK
-
AR
ADA 
PNP
Accumulation of 
toxic metabolites
RAG 1, RAG 2 
deficiency T
-
B
-
NK
+
AR RAG1/RAG2
Defective V(D)J 
recombination
ARTEMIS, 
KU70/80
DNA PK-cs, 
DNAligaseIV 
deficiency
T
-
B
-
NK
+
AR
ARTEMIS, KU70/80
DNA PK-cs, LIG4
Defective V(D)J 
recombination 
and DNA
double-strand 
break repair 
CERNUNNOS/X
LF deficiency
T
low 
B
low
NK
+ AR
CERNUNNOS/XLF
Defective V(D)J 
recombination 
and DNA 
double-strand 
break repair
Reticular 
Dysgenesis T
-
B
-/+
NK
-
AR AK 2
  
Increased 
apoptosis
ZAP 70 deficiency T
-
B
+
NK
+
AR ZAP70
Impaired T cell 
receptor signaling
MHC I deficiency 
MHC II 
deficiency
T
+
B
+
NK
+ 
T
low 
B
+
NK
 +
AR
TAP1/TAP2, 
TAPASIN 
HLA-DR, HLA-DP, 
HLA-DQ, HLA-DM, 
HLA-DO
Defective antigen 
presentation
CORO 1A  
deficiency T
-
B
-
NK
+
AR CORO1A
Abnormal actin 
polymerization
DOCK 8 
deficiency T
-
B
+
NK
+
AR DOCK 8
Defective  actin 
polymerization
Nude/SCID T
-/low
B
+
NK
+
AR FOXN 1
Defective 
intrathymic 
cross-talk
OS: Omenn syndrome; CID: combined immunodeficiency; HIES: hyper IgE syndrome.   
Table 1:  SCIDs classification according the molecular alterations and T, B, NK phenotype.  
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Most of the pathogenic mechanisms underlying SCIDs are related to molecular 
alterations of genes selectively expressed in hematopoietic cells. However, during the 
last years new non-hematopoietic causative genes of novel forms of SCIDs, involving 
organs different from immune system, have been identified. A prototype of SCID not 
primarily related to hematopoietic cell abnormality but rather to an intrinsic thymic 
epithelial cell defect is the Nude/SCID syndrome, identified in humans for the first time 
in 1996. This syndrome represents the human equivalent of the nude murine phenotype, 
described by Flanagan in 1966. In humans as in mice and rats (13), the Nude/SCID 
phenotype results from alterations of the FOXN1 gene (known in rats as Whn) (14, 15). 
The identification of this phenotype contributed to unravel important issues of T-cell 
ontogeny.
 In the future, further studies on PIDs will continue to unravel novel molecular 
and cellular mechanisms regulating development and function of several components of 
immune system and the complex mechanisms involved in autoimmunity and in immune 
surveillance against pathogens and tumoral cells.  
In this context my PhD program has been focused to the study of some 
Immunological disorders, in order to identify new scenarios in pathogenesis and 
therapeutic approaches. 
This thesis reports the results obtained during my PhD course in “Human Reproduction, 
Development and Growth” (XXVI Cycle) from 2011 to 2014.  During the past 3 years, 
my research has been focused in the study of the following lines of research: 
 functional role of FOXN1 transcription factor in the T-cell ontogeny; 
	

 role of common gamma chain (c) (X-SCID causing gene) in cell cycle 
progression and survival of continuous and primary human malignant cell line, 
clarifying its involvement in leukemogenesis; 
 forms of immunedeficiencies leading autoimmunity and cancer; 
 rare genetic syndrome involving immune system.


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CHAPTER I
“FOXN1 and T-cell development” 
The thymus is a complex organ with a central role in the immune system, since it is 
crucially required for T-cell differentiation and repertoire selection. This organ is 
organized in two lobes, each one divided in two main regions: a cortical and the dark 
cortical area, with a high number of lymphoid cells and epithelial cells, cortical thymic 
epithelial cells (cTECs); a light medullary area with a low number of mature T cells, 
named medullary TECs (mTECs), Hassall’s bodies (HB), macrophages, dendritic cells 
(DCs), B lymphocytes, and rarely myoid cells. Eventually, there is a transitional area, 
named cortico-medullary junction (CMJ), characterized by abundant blood vessels (16). 
These regions provide  appropriate cellular interactions, cytokines and chemokines 
necessary to induce the fully thymocyte development. An important feature of the 
thymic microenvironment is its 3D organization, consisting of an ordered architecture 
of TSCs, that represents a heterogeneous mixture of distinct cell types, including 
cTECs, mTECs, fibroblasts, endothelial cells, DCs, and macrophages (17). The 
requirement for the 3D-supporting stroma appears to be unique to the T-cell 
development, as the in vitro differentiation program of other hematopoietic lineages, 
including B and NK cells, does not require a 3D structure (18). This 3D configuration of 
the thymus maximizes the interactions between thymic components, allowing 
intercellular cross-talk integral to the development of both T cells and TSCs (19).  
The thymic T-cell development consists of several process that require the 
dynamic relocation of developing lymphocytes within multiple environments of the 
thymus (20).  The developmental pathway is divided into three subsequent steps, as 

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defined by peculiar immunophenotypic patterns: the CD4
−
CD8
−
 double negative (DN) 
stage, the CD4
+
CD8
+
 double positive (DP) stage, and the CD4
−
CD8
+
 or CD4
+
CD8
−
single positive (SP) stage (Figure 2). 
Figure 2: T-cell development and lympho-stromal crosstalk. Bone marrow HSCs enter into the 
thymus through CMJ, thanks to CCL19/CCL21, in embryonic thymus, and by interaction between P-
selectin and its cognate ligand PSGL-1 in adult thymus. Following, IL-7 signals drive the relocation of 
DN thymocytes from the cortex to the subcapsular region. DP thymocytes bearing TCR and capable of 
binding to self-MHC ligands are positively selected. This process is regulated by Pssr6 and b5t, which are 
expressed in cTECs. Developing thymocytes are relocated from cortex to the medulla by chemotactic 
attraction between CCR7 and the ligands CCL19/CCL21, expressed on the mTECs. Into medulla, 
dendritic cells and Aire-expressing mTECs eliminate self-reactive thymocytes through the negative 
selection.  
In mice, an immature single positive (ISP) CD8
+
CD4
−
 cell may be detected 
between the DN and DP stages. From the early T-cell lineage progenitor (ETP) stage to 
the double-negative 3 (DN3) stage, T-cell differentiation is independent from the TCR, 

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but is strictly dependent on the migration through the distinct thymic structures (21) and 
by the expression levels of specific transcription factors.  
The DN1 cell thymocytes show the potential to differentiate into B, T,myeloid, NK, and 
dendritic cells (DCs) (22, 23, 24) and exhibit a high proliferative ability. The 
upregulation of a number of genes involved in the process, including genes needed for 
rearrangement and/or expression of the pre-TCR signaling complex components allows 
the transition to DN2 phase (25). The thymocytes at DN2 stage are fully responsive to 
IL-7 and SCF due to the high expression of IL-7R and c-kit. Moreover, the genes 
which favor the myeloid, NK, and dendritic fate, so-called T-cell antagonists, as PU.1, 
stem-cell leukemia (SCL also known as TAL1), GATA binding protein-2 (GATA-2), 
and CCAAT-enhancer binding protein  (C/EBP) are silenced before that  or 
selection takes place (Figure 2) (26). During this phase only a few transcription factors, 
including the zinc-finger transcription factor, the tumor suppressor factor B-cell 
lymphoma/leukemia 11b (BCL-11b) (27), basic helix-loop-helix (bHLH) transcription 
factors alternative (HEBalt) (28), and, more transiently, glioma-associated oncogene 2 
(GLI-2), a transcription factor involved in the sonic hedgehog signaling (29), are 
expressed. The DN2 thymocytes don’t completely lost, the ability to differentiate into 
NK cells, DCs, or macrophages (30, 31).
The following DN2 to DN3 stage transition requires the expression of different 
arrays of genes, as Runt-related transcription factor 1-Core binding factor  (Runx1-
CBF) complexes, the transcription factor Myb, GATA-3, and Bcl-11b, which allow 
full TCR gene rearrangement in thymocytes, that become competent to undergo -
selection (32, 33). Several important events occur during the DN2/3 transition, as the 
induction of recombinase activating gene-1 (Rag-1) and Rag-2, the upregulation of pre-


T (pT), and the rearrangement of TCR and . CD3 and IL-7R (CD127) are also 
upregulated at this phase (34) along with the turn-on of the lck tyrosine kinase 
implicated in the pre-TCR and TCR signaling (35). At this point, T-cell precursors lose 
their capability to follow a non-T-cell fate choice (36). The cells overcoming -selection 
express the pre-TCR complex on their surface and reach the DN3 stage (37). At the 
DN3 stage, pre-TCR signaling results in the downregulation of CD25, pT, Rag-1, and 
Rag-2, which leads to the appearance of DN4 cells. These cells are fully committed to 
the  T-cell lineage (38). After -selection, the thymocytes, which have properly 
rearranged TCR chains, show a burst of proliferation and a subsequent upregulation of 
CD8 and then CD4. At this point, the cells become double positive (DP). Eventually, 
DP cells rearrange TCR gene, leading to TCR assembly into a TCR complex. The 
newly generated DP thymocytes are localized in the cortex and express low levels of the 
TCR complex. This DP population consists of T cells with an unselected repertoire
(39, 40). Following that, positive and negative selections take place. In the cortex, the 
DP thymocytes interact through their TCR with peptide-MHC complexes expressed by 
stromal cells, as cTECs and dendritic cells (41). When TCR interacts with low-avidity 
with the peptide-MHC ligands, DP thymocytes receive survival signals. This process, 
referred to as positive selection, allows “productive” T cells to potentially react to 
foreign antigens, but not to self-antigens. Lately, positively selected DP thymocytes are 
ready to differentiate into SP cells, that is, CD4+CD8
−
 or CD4
−
CD8
+
 and relocate into 
the medulla. At this site, newly generated SP thymocytes are further selected by the 
medullary stromal cells, including autoimmune regulator- (AIRE-) expressing mTECs 
(42). The cells which are reactive to tissue-specific self antigens are deleted, thus 
avoiding autoimmunity. SP thymocytes egress from the thymus as recent thymic 

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emigrants (RTEs), naïve cells expressing the CD62 ligand (CD62L), also known as 
lymphocyte- (L-) selectin, CD69, and the CD45RA isoform (43). 
Of note, the immature thymocytes journey through the thymus has also the 
additional effect of promoting the differentiation of thymic stromal precursors into 
mature thymic epithelial cells, thus playing an important role in the formation of the 
thymic microenvironment (44, 45).  
1.1 “FOXN1: a critic developmentally-regulated transcription factor involved in T-
cell ontogeny” 
Thymus anlagen arises as bilateral structures from the third pharyngeal pouch in the 
embryonic foregut (20, 46).  The seeding with lymphoid progenitor occurs as early as 
embryonic day 11.5 in mice and the eighth week of gestation in humans (47, 48).  In 
both human and mice, the primordial thymic epithelial cells are yet incompetent to fully 
support T-cell development and this essential capacity is dependent on the 
transcriptional activation of the FOXN1 gene in the thymic epithelium (49). 
FOXN1 gene, spanning about 30 kb, is localized on chromosome 17 in human 
and on chromosome 11 in mice. The gene is composed of nine exons, one of which 
(exon 1) is non-coding. Human and mouse FOXN1 genes show identical genomic 
structures, with the same number, location, phase and size of introns (49). The genes 
located next to FOXN1 are also identical in both species. FOXN1 has two alternative 
first exons that show tissue specificity, suggesting the existence of two different 
promoter sequences. FOXN1 gene encodes for a member of the forkhead/winged helix 
class proteins, a large family of transcriptional factors implicated in a variety of cellular 
processes (50, 51). Of note, more than 100 members of this family have been identified. 

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FOXN1 acts through its target genes to regulate the differentiation of epithelial 
cells, after activation through phosphorylation, that promotes its nuclear translocation. 
Into the nuclei it interacts with DNA as a monomer through its forkhead box (52, 53). 
The signaling pathways that promotes FOXN1 expression is mainly the wingless (Wnt) 
proteins (54) and bone morphogenetic proteins (BMPs) (55) in both autocrine and 
paracrine fashions (56) During embryogenesis, FOXN1 is expressed in several 
mesenchymal and epithelial cells, including those of the liver, lung, intestine, kidney 
and urinary tract (57). In adult life, FOXN1 is mainly expressed in the thymus and skin 
epithelial cells, playing a critical role in differentiation and survival of these epithalia 
(58, 59, 13).  
Maturation of the thymic epithelial meshwork during thymic organogenesis 
occurs in two genetic stages (60, 61). The first stage involves FOXN1-independent 
induction and outgrowth of the thymic epithelial anlage from the third pharyngeal 
pouch. Through studies on animal models carrying molecular alterations distinct genes, 
the key role of several transcription factors involved in the thymus organogenesis and 
TEC-sublineage specification process have thus far been identified (62). In particular, 
several genes, including Tbx1 (63), Pax1, Pax3, Pax9 (64, 65, 66), Hoxa3 (67), Eya1, 
and Six1 (68) have been shown to play a central role in the thymus ontogeny. The 
second FOXN1-dependent genetic step involves epithelial patterning and differentiation, 
as precursor epithelial cells differentiate into mature and functional cTECs and mTECs 
from the same bipotential TEC progenitor (69, 70). It has been reported, that FOXN1 is 
differentially expressed during the TE-lineage specification, since it is expressed in all 
TECs during the prenatal life, but not in all TECs postnatally, indicating that the gene is 
highly developmentally regulated. In keeping with this, a different role of FOXN1 in  

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pre-natal and post-natal life has been documented. In the fetal stage, FOXN1 mainly 
regulates TEC patterning. Since both cTECs and mTECs arise from the same bipotential 
TEC progenitors and FOXN1 regulates the process of differentiation, it is 
straightforward to conclude that both mTECs and cTECs are equally FOXN1-dependent 
during fetal thymic organogenesis (71). However, in the postnatal thymus, mTECs with 
the keratin type K5
+
 and K14
+
, which are similar to epithelial stem cell markers and 
exhibit activity in the skin and mammary gland epithelial progenitor cells, were more 
sensitive to loss of FOXN1; while cTECs are keratin type K8
+
 and K18
+
, which the 
same as mature epithelial markers and as terminally differentiated epithelial cells in the 
apical layer of stratified squamous epithelium of the skin, were not sensitive to loss of 
FOXN1. 
Moreover, recent reports highlighted a central role for Foxn1 in TECs homeostasis in 
the adult thymus and its necessary role for the functionality and survival of adult TEC 
progenitors (72), expressing K5
+
 and K14
+
 markers.  This role in adult thymus seems to 
be exerted in cooperation with other stem cell-related genes, such as p63.  Of note, the 
transcription factor p63, encoding for multiple isoforms (73), drives the proliferation of 
TEC progenitors (74). Of note, it has been hypothesized that p63 and Foxn1 could act 
synergistically through the formation of a p63-Foxn1 regulatory axis aimed at 
regulating TECs homeostasis. However, the molecular mechanism through which the 
proliferation regulator p63 and differentiation regulator Foxn1 collaborate in this axis 
are still unclear. 
 In the skin, FOXN1 regulates cell growth and differentiation and it is primarily 
expressed in the first suprabasal layer that contains keratinocytes in the early stages of 
differentiation, leaving the cell cycle and initiating terminal differentiation (75). In the 

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hair follicle, FOXN1 expression is restricted to a specific compartment, the 
supramatrical region (75), where the cells stop to proliferate and begin terminal 
differentiation (76). Of note, high levels of FOXN1 mRNA were found in co-culture of 
skin cells along with hematopoietic precursor cells (HPCs), suggesting a role of human 
skin in supporting the human T-cell development (77). 
These data have been published as Reviews on Frontiers Immunology and
International Reviews of Immunology, for the manuscripts see below.  
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1.2. The human NUDE/SCID phenotype: a model to study T-cell development 
Recessive mutations in the FOXN1 gene lead nude phenotype, described for the first 
time in mice. This murine model was described by Flanagan in 1966, when 
spontaneously appeared in the Virus Laboratory of Ruchill Hospital in Glasgow (UK) 
(13, 51). Mice homozygous for the mutation “nude” are hairless, have retarded growth, 
decreased fertility, and die by 5 months of life for infections. Thymus abnormality, or 
even absence, is the hallmark of the nude phenotype. In fact, these animals develop a 
profound T-cell deficiency and a severely impaired immune response of either cell-
mediated and, indirectly, humoral immunity (78). Today, nude mice are a widely use 
model in immunology, dermatology, cosmetic, oncological and transplantation research 
fields because of their defect in allo- or xeno-transplantation rejection due to the 
absence of a functional immune system (79). In man, the prototype of an athymic 
disorder has long been considered the DiGeorge’s Syndrome (DGS), even though main 
features of athymic murine model and human disease, including immunological signs, 
are not completely overlapping. The human counterpart of murine nude phenotype was 
described for the first time in 1996 by our research group, as a novel form of SCID 
caused by an intrinsic defect of the thymus (MIM 601705) in 2 patients born to 
consanguineous parents originating from a small community in southern Italy. The 
hallmarks of this human novel clinical phenotype are ectodermal abnormalities, as 
alopecia and nail dystrophy (80), and a profound T-cell defect (51). Of note, the nail 
dystrophy can be observed also in subjects carrying the genetic alteration in 
heterozygosity. The most frequent nail alteration is the koilonychia (spoon nail), 
characterized by a concave surface and raised edges of the nail plate, associated with 
significant thinning of the plate itself; a canaliform dystrophy associated to a transverse 

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groove of the nail plate (Beau line) may also be found (80). The first described human 
FOXN1 mutation was a C792T transition in exon 5, resulting in the nonsense mutation 
R255X (13). This mutation lies upstream of the DNA binding and trans-activation 
domain of this transcription factor, so that translated protein, if any, would be 
completely non-functional, similar to the previously described rat and mouse Foxn1 
mutations (81). 
Recently, the identification of a human FOXN1
-/-
 fetus gave the unique 
opportunity to study in humans the T-cell development in utero, in the absence of a 
functional thymus.  Vigliano et al., documented a total blockage of the CD4
+
 T-cell 
maturation and a severe impairment of CD8
+
 cells, with an apparent bias towards 
TCR
+
 cells.  In this case, the congenital absence of the thymus was due to R255X 
missense mutation in the FOXN1 gene (82).  In particular, it has been reported that, in 
the absence of FOXN1, a few not functional CD8
+
 cells could develop, mostly bearing 
TCR in the absence of CD3. Further analysis of the fetal RNA, performed to evaluate 
the variable-domain -chain (V) families’ usage among T lymphocytes, revealed that 
the generation of TCR diversity occurred at some extent in the FOXN1
-/-
 fetus, but was 
abnormal. Thus, these data provided a further evidence of the crucial role for FOXN1 in 
the early prenatal stages of T-cell development and not in the B- and NK-cell 
differentiation, these populations being normally present in the Nude/SCID fetus (82). 
A similar impairment of the T-cell differentiation with a selective blockage of CD4 
differentiation but not of CD8, was detected in murine models characterized by the 
absence of the nuclear high-mobility group (HMG) box protein TOX (15). 
The identification of a limited number of CD8
+
 cells bearing the TCR suggests 
that this cell population may develop at extrathymic sites in a FOXN1-independent 

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manner, even though they are unable to sustain a productive immune response into the 
periphery. Indeed, evidence exists indicating that T cells may also differentiate at 
extrathymic sites, as intestine and liver (83, 84, 85). Of note, the majority of thymus-
derived T lymphocytes bears the  chains of TCR and a few of them express the 
heterodimer (86), while the T-cell pool developed outside the thymus is characterized 
by a higher proportion of TCR
+
 T cells expressing the CD8 homodimer, instead of 
the CD8 (87).  Moreover, also DN T cells (CD3
+
CD4
–
CD8
–
) and lymphocytes 
expressing CD7 and CD2 in the absence of CD3 (CD2
+
CD3
–
CD7
+
) are generally 
considered of extrathymic origin (87, 88), suggesting the existence of extrathymic sites 
of thymus-independent and FOXN1-independent T lymphopoiesis.  
These data have been published as Reviews on Clinical and Developmental 
Immunology, for the manuscript see below.  
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1.3. Molecular evidence for a thymus-independent partial T-cell development in a 
FOXN1
-
/
-
 athymic human fetus 
Genetic alterations of FOXN1 gene are responsible in humans, mice and rats of the 
Nude/SCID phenotype, characterized by athymia and severe blockage of T-cell 
ontogeny. By taking advantage of the opportunity to study tissue samples from a human 
Nude/SCID fetus, we addressed the issue of defining the role of the gut as alternative 
site of T-cell ontogeny in a thymus-independent and FOXN1-independent fashion. 
Recently, we demonstrated the role of the gut as alternative site of T-cell 
ontogeny in a thymus-independent and FOXN1-independent fashion. In our study we 
demonstrate that, in the absence of the thymus, a few rare T lymphocytes are detectable 
in the cord blood, even though a complete blockage of the CD4
+
 population was 
documented (82). In the Nude/SCID fetus, most of the rare CD3
+ 
cells were CD4 and 
CD8 double negative. A novel population of T cells with similar phenotypic 
characteristics, CD3
+
B220
low
CD4
-
CD8
-
, exhibiting an impaired proliferative response 
but producing cytokines and expressing high levels of CD25.  In the Nude/SCID, 
similarly to the control fetus, a CD3
-
CD7
+
CD2
+
 population was found, suggesting that 
the differentiation of this population is FOXN1-independent. In human fetal gut, within 
the CD3
-
CD7
+
 population a proportion of these cells is able to develop into CD3
+
 T 
cells presumably in a thymus-independent manner (88). The identification of CD7
+
lymphoid-restricted progenitors in the fetal bone marrow (89) indicates that the CD7 
expression and lymphoid commitment occur before the migration to the thymus. Thus 
far, it has been shown that T-cell precursors and thymus-independent NK-cell 
precursors start to express the CD7 molecule in fetal liver and bone marrow since the 5
th
week of gestation (90).  Later, CD7
+
 cells migrate to the thymus where they undergo to 


a series of maturational stages eventually developing into fully mature T cells (91).  In 
the absence of the thymus, it is plausible that this population could represent 
extrathymic originated NK-cell precursor as suggested also by the co-expression of the 
CD2 molecule. In the epithelium of the small intestine, lymphocytes expressing CD7 
and CD2 but not CD3 have already been documented (91).  However, the expression of 
CD7 in the absence of the CD2 marker is generally considered a commitment toward 
the T-cell lineage. Of note, in the Nude/SCID and the control fetuses, a CD3
-
CD7
+
CD2
-
population was identified, thus supporting the hypothesis that this precursor 
differentiates toward the T-cell rather than NK-cell lineage. There is also evidence 
indicating that the majority of the CD3
-
CD7
+
 population express the CD8 homodimer 
and that these cells represent the precursors of the CD3
+
 mature cell population (88). Of 
note, in mice the expression of the CD8 homodimer has only been documented on 
extrathymically derived IELs (87). However, whether cells expressing the CD8 
homodimer are really locally produced in the intestine or rather they require a functional 
thymus to be generated is still controversial. In support of a thymus-independent 
process, in nude mice the presence of TCR
+
CD8
+
T-IELs has been reported and 
interpreted as a demonstration of a local T-cell differentiation process in the gut. 
However, these CD8 T-IELs are much lower in nude mice than in euthymic mice 
(93).  In keeping with this, neonatal thymectomy leads in mice, to a decrease of such 
cells, similarly to what observed in the Nude mice (94).  In our athymic human model 
we found a negligible number of cells expressing the CD8 homodimer, thus 
indicating the requirement of an intrathymic step of differentiation for these cells.  
Differently, we previously documented in the Nude/SCID human fetus a considerable 
number of CD3
-
CD8
+
TCR
+
 cells, which also comprises cells with the CD8
	

heterodimer (82). Under certain circumstances, IELs may express only a partial CD3 
complex bearing rare message of the  chain although the T-cell commitment is 
established by the presence of pT transcript (95). Moreover, a number of studies have 
shown that the TCRs of extrathymically derived T cells are made of either  or 
heterodimers, but the TCRγδ+ cells are prominent (96). In our study, a definitive 
demonstration of the local production of T lymphocytes in the intestine in a thymus-
independent manner came out from the observation that in the Nude/SCID, CD3
+
 cells 
and a few CD8
+
 cells were detected in the fetal intestine and CD3 transcript was 
documented, thus indicating that the process does not require the FOXN1 transcription 
factor. In particular, CD3
+
 cells appeared as aggregates in the intestinal crypts. Intestinal 
T lymphocytes also exhibited a CD45RA
+
 naive phenotype. As expected, CD4
+
 cells 
were absent in either intestine or liver of the Nude/SCID fetus. 
 The hallmark of the T-cell ontogeny is the TCR gene rearrangement process, 
characterized by distinctive patterns of gene expression, such as RAG1 and 2 in 
lymphocytes of both T- and B-cell lineages, which are responsible for the DNA 
cleavage (97).  This process results, in T lymphocytes, in V(D)J recombination.  
Another T lineage specific marker is the pT expression, in that mature and immature B 
cells, myeloid cells, NK cells and pluripotent stem cells are pT negative. This 
molecule associates with the mature TCR -chain allowing rearrangement of the -
chain gene (98).  The expression of the surrogate TCR chain pT is upregulated during 
the DN3 stage of the T-lymphocyte development, along with the expression of the RAG 
genes (99)  pT-expression is also found in pro-T cells at extra-thymic sites of the T cell 
development (100). Also in IELs RAG1 and pT mRNAs are expressed, thus indicating 
an ongoing TCR gene rearrangement locally in the intestine (101). We found that the 



relative expression of RAG1 and RAG2 was approximately 50% of the control and pT
was expressed, as well, accounting for 10% of the control.  Although RAG1 and RAG2 
enzymes are highly expressed also in pro-B and pre-BII cells, providing the 
rearrangement of B-cell antigen receptor gene (102), the expression of the pT gene 
implies an active process of a thymus-independent T-lymphopoiesis in the intestine in 
our model.  Moreover, we previously documented that in the Nude/SCID cord blood the 
generation of TCR diversity toke place but was consistently impaired with 2 V
families that represented more than 60% of the whole TCR.  In this study, we found that 
the spectratype of intestinal T cells paralleled the cord blood spectratype in that all the 
families expressed in the CBMC were also expressed in the intestine.  This finding 
indicates that, in the absence of the thymus, the development of intestinal lymphocytes 
only expressing a limited repertoire occurs as an active process in a thymus-independent 
fashion. The expression of the E7 integrin CD103 helps direct above originated 
lymphocytes to migrate into the intestine through cognate interaction with the specific 
E-cadherin ligand expressed on epithelial cells (103, 104).  In this study, the absence of 
CD103 marker in the intestine further would suggest that the intestinal lymphocytes 
were not elsewhere  originated cells migrated into the intestine. 
 In humans, alterations of the FOXN1 transcription factor does not interfere with 
the production of B and NK cells.  The normal presence of stem cells, B and NK cells in 
the Nude/SCID intestine, parallels the relative presence of these cells in the cord blood 
(105).  In contrast, the absence of NK cells in both Nude/SCID and control fetal liver 
tissues would indicate that NK cell presence in the liver occurs at a later fetal age.  
Eventually, these findings confirm that at 16 weeks of gestation the development of 
mature B and NK cells is a thymus-independent process.  


 To conclude, our results represent the first formal demonstration that an 
extrathymic lymphopoiesis in the absence of the thymus and in a FOXN1-independent 
manner occurs in humans, even though it is not sufficient per se for a productive 
immune response in the peripheral blood. 
These data have been published as Article on PlosOne, for the manuscript see below.  
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1.4. A “thymic organoid” leads to differentiation toward T-lineage committed cells 
in vitro 
The thymus capability to lead differentiation of hemopoietic stem cells (HSCs) into T 
lymphocytes is mediated by specialized TECs. The three-dimensional organization of 
thymic stromal cells maximizes the interaction of developing thymocytes with TECs, 
allowing intercellular cross-talk required to development of both T cells and TECs 
(106).   
 A remarkable number of similarities are shared between the epithelial and 
stromal cells of the thymus and keratinocytes and fibroblasts of the skin. Both thymic 
and skin epithelial cells selectively express the FOXN1 transcription factor, which plays 
a critical role in differentiation and survival of these specialized cells (107, 108). 
Hassall corpuscles, a product of medullary thymic epithelial cells, contain keratins 
identical to those in the stratum corneum of skin. In addition, keratinocytes express 
many of same keratins expressed in TECs (109). Moreover, the Notch pathway is 
shared between thymic stroma and skin elements, since it plays an important role in 
regulating epidermal differentiation, in early stages of thymocyte maturation and T-cell 
lineage commitment (110).  By contrast, a profound difference between thymus and 
skin is the architecture of each organ, in that the skin epithelial cells are organized in a 
two-dimensionally (2D) oriented fashion differently from epithelial cells of the thymus, 
which are organized in a 3D configuration (111). 
By taking advantage from the similarities shared between keratinocytes and 
thymic epithelial cells (TECs), we used human keratinocytes seeded with human 
fibroblasts on a 3D poly(-caprolactone) scaffold, by mimicking the 3D configuration of 
the thymus, to verify the ability of these cellular elements, spatially arranged as 


described, to reproduce in vitro a microenvironment able to replace TECs in supporting 
HSCs differentiation.  
 The ex vivo reproduction of thymus microenvironment, positively selected 
CD34
+
 HSCs (>80%) were seeded in the scaffold and maintained in culture for 5 weeks 
in the presence of pro-lymphopoietic cytokines, including IL-7 and IL-15, as well as 
Flt-3 ligand. Subsequently, we performed an immunophenotypic analysis at different 
time-point to observe developmental changes that occurred when CD34
+
 HSCs were 
induced to differentiate in the composites, by using flow cytometry to detect expression 
of surface antigens critic for T-cell development, such as CD7, CD1a, CD3 and CD8 
CD4. Of note, it has been shown that, at that the earliest stages of T-cell development, 
thymic precursors express CD7 surface antigen (112), since Notch signaling pathway 
induces the differentiation of multipotent haematopoietic progenitors into 
CD7
+
CD34
+
CD45RA
+
 early T-cell precursors (113). Subsequently, the expression of 
CD1a
+
 represents a critical stage to T-cell commitment and the cell population 
CD7
+
CD1a
+
 has been previously identified as early T cells (114). At the next 
developmental stage, the pre-T cells express CD4, but not yet CD3 and CD8, and are 
thought to be CD4 immature single-positive cells. Eventually, the expression CD4 and 
CD8 is required to generate double-positive, which then mature in single positive CD4 
or CD8 cells (115). In the multicellular biocomposite, we observed de novo generated 
CD7
+ 
cells by the third week of culture. At the fifth week of culture, these cells acquired 
the CD1a marker. In addition, we detected in culture CD4 immature single-positive 
cells, not yet expressing CD3 and CD8 markers. Taken together, these data 
demonstrated that in the “thymic organoid”, containing skin-derived elements in the 
absence of thymic stroma, in presence of IL-7, IL-15 and Flt3-ligand, HSCs did start 


differentiating and that the process was also directed toward a T-cell lineage 
commitment. To confirm T-cell lineage specification, the expression levels of selected 
T-lineage specific genes, including TAL-1, Spi-B, RAG1/2 and PTCRA, do not 
expressed in keratinocytes or in fibroblasts, were studied by real-time PCR.  
Of note, at early stage of T-cell development, the cells express at high levels 
many genes (Sfpi1 (PU.1), Tal1 (SCL), Id2, Cebpa, Bcl11a) functionally implicated in 
non-T cell hematopoietic differentiation programs (116,  117,  118), while genes 
necessary for T-cell gene expression program are downregulated, thus implying a 
multilineage differentiation potential of early thymocytes. Following, the 
downregulation of these molecules is strongly correlated with the activation of T-cell 
gene expression program, whose hallmarks are the expression of Spi-B, which is 
downregulated during the early stages of T-cell development (DN1 and DN2) and 
upregulated at DN3 stage, and the genes involved in the T-cell receptor re-arrangement, 
such as RAG1/2 and PTCRA (119, 120, 121). Our data showed both down-regulation of 
TAL1 and up-regulation of Spi-B in the multicellular composite, consistently with the 
loss of the multilineage differentiative potential. In addition, PTCRA and RAG2
expression was found at the third week of the culture, suggesting recombination 
activity. These molecular events were not observed in the control systems and are 
consistent with the immunophenotypic data, supporting an ongoing process.  
In conclusion, our results indicate that, the “thymic organoid”, containing skin-
derived elements in the absence of thymic stroma, leads to HSCs differentiation and 
toward a T-cell lineage commitment in the presence of IL-7, IL-15 and Flt3-ligand, 
even though fully mature single-positive T cells were not generated in the system. 


These data have been published as Article on International Immunology, for the 
manuscript see below. 
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1.5. In vitro reprogramming of human fibroblasts in medullary Thymic Epithelial 
Cells (m TECs) 
By taking advantage from the similarities shared between keratinocytes and TECs, we 
used keratinocytes seeded with fibroblasts on a 3D poly(-caprolactone) scaffold to 
replace TECs in supporting HSCs in vitro differentiation. Although a T-cell 
commitment was achieved, we couldn’t generate fully mature T cells. To reproduce a 
microenvironment capable to support a full T-cell differentiation, our further approach 
was to develop in vitro mTECs from human fibroblasts by nuclear reprogramming 
technology. 
 Embryonic stem (ES) cells, derived from the inner cell mass of mammalian 
blastocysts, have the ability to grow indefinitely while maintaining pluripotency. The 
human ES cells, because of their combined ability to proliferate indefinitely and to 
differentiate in different somatic cells, are suitable for various purposes, including 
understand disease mechanisms, to screen effective and safe drugs, and to treat patients 
of various diseases and injuries, such as juvenile diabetes and spinal cord injury. 
However, ethical controversies does not allow the use of human embryos to derive 
human ES cells. In addition, it is difficult to generate patient- or disease-specific ES 
	

cells, which are required for their effective application. To circumvent these issues the 
pluripotent phenotype has been induced in somatic cells by using nuclear 
reprogramming (122). 
Yamanaka and Takahashi demonstrated that induced pluripotent stem cells 
(iPSCs) can be generated from mouse embryonic fibroblasts (MEFs) and adult mouse 
tail-tip fibroblasts by the retrovirus-mediated transfection of four transcription factors, 
namely Oct3/4, Sox2, c-Myc, and Klf4 (123). Mouse iPS cells are indistinguishable 
from ES cells in morphology, ability to proliferate, gene expression, and ability to 
generate teratoma. Furthermore, when transplanted into blastocysts, mouse iPSCs can 
give rise to adult chimeras, which are competent for germ-line transmission. These 
results demonstrated that pluripotent stem cells can be generated from somatic cells by 
the combination of a small number of factors physiologically expressed in pluripotent 
cells. 
The reprogramming of adult cells is a striking methodology that allows to obtain 
pluripotent stem cells, but this method have some limitation, including the   Currently, 
the delivery of factors for iPS induction can either be achieved with integrating or non-
integrating methods, which differ for safety and efficiency (Table 2). The retroviral and 
lentiviral vectors show high reprogramming efficiency, but the resulting iPSCs have 
randomly distributed viral transgene insertions, thus increasing tumor formation risk. 
On the other hand, the transient expression methods, such as adenovirus, plasmid and 
cell penetrating protein, are of low efficient but they are safe and preserve the genomic 
integrity of iPS cells (124, 125). 
	
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Table 2: Methods of factor delivery for nuclear reprogramming (125).
Human wild-type skin fibroblasts (600000 total cells) have been reprogrammed by 
introducing 3 episomal vector containing cDNA of human Oct3/4, Sox2, Klf4 and L-
Myc (Figure 3) and by using electroporation.  
	

Figure 3: Maps of episomal vector containing of human Oct3/4, Sox2, Klf4 and L-Myc. 
Fibroblasts trasfected have been plated on mitomycin C-treated  feeder cells MEFs in a 
six-well plates, with Fibroblasts Medium Culture without Gentamicin. The next day, the 
medium has been replaced with new Fibroblasts Medium Culture enriched with 
Gentamicin. At the 4
th 
day, the medium for primary hES cell culture (hESC medium), 
		

supplemented with FGF2 (10 ng/ml), SB431542 (2M), PD0325901 (0.5 M),  
Valproate (500 M), has been used. hESCs medium has been replaced every 2 days and 
the molecule have been added until 14 days after trasfection. ES-like colonies first 
became visible approximately on 20 days after post-transfection, with a well delimited 
and tightly packed structure. The cells forming the colonies show large nuclei and scant 
cytoplasm (Ratio 1/1) (Figure 4).  
Figura 4: iPSCs clone.  A representative clone is showed in the figure. The clone shows the peculiar ES-
like clone morphology, namely well delimited and packed, round shape distinct from fibroblasts 
background, and cells forming the colonies with large nuclei and scant cytoplasm. 
The iPSCs clones have been picked until 20 days after trasfection, have been amplified, 
on feeder layer of BJ1-FGF2 fibroblasts treated with mytomic-C, and freeze by using 
CryoStor
TM
CS10 reagent, after 5 passages. It has been obtained 10 iPSCs clones. 
Moreover, every 2 weeks the mycoplasma test has been performed.  
The characterization of iPSC lines, using a standard series of Quality Control Assays, is 
necessary to confirm the pluripotency of iPS clones obtained by reprogramming of 
somatic cells. The Quality Control Assays include: morphology, alkaline phosphatase 
labeling, pluripotency marker expression, in-vitro embryoid body and in-vivo teratoma 
differentiation, karyotype analysis, and eventually
	


Concerning the Quality Control, the iPS clones obtained exhibited the peculiar ES-like 
clone morphology, as showed in the figure 4. In addition, the Alkaline Phosphatase 
staining have been performed on iPSCs clones to proof pluripotent properties of these 
cells, since Alkaline Phosphatase activity is a qualitative marker of pluripotent cells. 
The color purple  indicate a positive staining for Alkaline Phosphatase, suggesting the 
presence of pluripotent cells in culture (Figure 5). 
Figure 5:  Alkaline Phosphatase staining of iPSCs after passaging. Purple staining identify 
iPSCs, since high Alkaline Phosphatase can be detected in pluripotent stem cells. 
However, additional Quality Control Assays have to be performed to provide 
conclusive evidence of iPSC lines pluripotency. 
The future approach will be to differentiate iPSCs  into  mTECs though  the  
addition  of a culture medium enriched with key factors for the differentiation, produced 
under physiological circumstances during thymic organogenesis in humans. This in 
vitro model of mTECs will help further clarify the central role of the FOXN1 


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transcription factor in the Nude/SCID syndrome (the prototype of athymic syndrome 
and T-cell defect) pathogenesis and explore the possibility to replace TECs with 
FOXN1-expressing keratinocytes.  
1.6. Conclusive remarks
The thymus is the primary lymphoid organ with the unique function to produce and to 
maintain the pool of mature and functional T cells, through the functions specialized of 
thymic stromal cells (TSCs) and peculiar 3D architecture, which allows a proper 
intercellular cross talk. The discovery of disease models associated to mutations of 
genes implicated in T-cell development, thymus specification and TECs differentiation, 
provided new and conclusive insights regarding the pathways, the genes, and the 
molecular mechanism governing these processes and stromal functionality. The studies 
on both murine and human Nude/SCID phenotype greatly contributed to unravel 
important issues of the T-cell ontogeny and in particular of the role of FOXN1 in this 
process. In spite of the well documented knowledge on the role of the thymus to drive 
T-cell development, some still unsolved issues in human athymic conditions indicate 
that an in-depth information of the overall process is still to be achieved and, in 
particular, the involvement of different tissues in T-cell ontogeny must be definitively 
clarified. 
The development in vitro of cellular models of TEC lineage differentiation, by 
using the technology of nuclear reprogramming, will be certainly useful to better 
characterize the discrete stages of the TECs differentiation and the molecular 
mechanism involved in the process. Eventually, the in vitro re-build of a thymic 


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environment capable to reproduce tissue features of primary lymphoid organs (77) 
could be a promising and valuable tool for the treatment of congenital athymia, 
including FOXN1 deficiency, along with the thymus transplantation, which is emerged 
as a potential treatment for these disorders.   


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CHAPTER II 
“X-linked Severe Combined Immunodeficiency due to mutations of c” 
X-SCID is the most common form of SCID, accounting for approximately half of all 
cases and it is the main form of T
-
B
+
NK
-
, in which T cells and NK cells are absent or 
profoundly diminished in number, whereas B-cell number is normal. X-SCID is 
generally fatal unless any treatment aimed to immune system reconstitution. Nowadays, 
the only treatment for X-SCID is bone marrow transplantation (BMT) from an HLA-
matched related donor, which confers to children affected by SCID at least a 70% 
chance of cure. Moreover, the use of a not fully HLA-matched donor increases the 
immunologic complication such as graft-versus-host disease (GVHD) associated with a 
potential long-term decline in immune cell function. X-SCID has recently been 
successfully treated by gene transfer therapy to hematopoietic stem cells, but serious 
adverse events have also occurred. In two different gene transfer clinical trials for X-
SCID, immunological reconstitution has been observed, thus implying the clinical 
feasibility of introducing a therapeutic gene into hematopoietic stem cells (126). 
Unfortunately, leukemia occurred in five patients enrolled in the trials, suggesting that 
insertional mutagenesis and occurrence of the oncogenesis are adverse effect of gamma-
retroviral gene transfer treatment. The discovery of the X-SCID disease gene has led to 
increased appreciation of the immunologic characteristics of this form of SCID and 
elucidation of molecular responses of lymphocytes to cytokines. 


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2.1. The c-signaling and spontaneous or induced cell proliferation 
The cytokine receptors are classified into five families on the bases of extra- and intra-
cellular domains structure affinity: the cytokine receptor superfamily, interferon 
receptor family, tumor necrosis factor (TNF) receptor family, tumor growth factor 
(TGF),  receptor family and IL-8 receptor family (127). The cytokine receptor 
superfamily is the largest family, including the receptors for IL-6, IL-11, Oncostatin-M 
(OSM), Ciliary Neurotrophic Factor (CNTF) and Leukemia Inhibitory Factor (LIF) 
containing the common gp130 (128), the receptors for IL-3, IL-5 and granulocyte, 
macrophage colony, stimulating factor (GM-CSF) sharing the common  subunit, and 
eventually the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 and Growth Hormone 
Receptor (GH-R) sharing the common c element (127). The IL2RG, localized to 
chromosome Xq13, encodes a c transmembrane protein, the transducing component 
shared by the cytokine receptor superfamily (129). The c is expressed in lymphocytes 
and also in other cell types. It is clear that c cytokines regulate several aspects of 
immune activation. These molecule plays an important role in supporting survival, 
proliferation and effector functions of activated immune cells. Of note, regulation of cell 
survival and cell apoptosis is a delicate teamwork and a balanced act of all c-dependent 
cytokines is of crucial importance (Figure 6) (130). 


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Figure 6: The c-dependent cytokines and their receptors (131). 
The biological effects of cytokines are mediated through interaction with specific 
receptors, that leads to phosphorylation of intracellular proteins. Members of the 
cytokine receptor superfamily do not have intrinsic kinase activity, but the interaction 
with the specific ligands induces the recruitment of intracellular protein kinases. The 
tyrosine kinases that couple extracellular cytokine binding to intracellular 
phosphorylation of protein substrates, and eventually to cell growth and differentiation, 
are members of the Janus-associated kinase (JAK) family. Thus far, four distinct 
members of the JAK family are known in humans: JAK1, JAK2, JAK3 and Tyk2. 
Members of the IL2RG superfamily physically are associated with JAK1 and JAK3 
(132).  
Several signaling pathways are elicited by JAK1/JAK3 activation in members of the 
cytokine receptor superfamily. First, the phosphorylated cytokine receptor may 
associate with the adaptor SHC, which is itself phosphorylated and binds to Grb2. Grb2 
may thus anchor to Sos, the Ras guanine nucleotide exchanging factor. Membrane 
translocation of the Grb2/Sos complex catalyzes the conversion of inactive GDP-bound 
Ras to the active GTP-bound state, leading the activation of Raf-1 mitogen-activated 


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protein kinase (MAPK) and eventually in the induction of immediate-early genes (c-fos, 
c-jun) (133). Subsequently, the JAK activation  by c-dependent cytokines leads to the 
binding and phosphorylation of insulin receptor substrates (IRSs) (134). The activation 
of IRS induces the binding of its SH2 domain to the p85 subunit of 
phosphatidylinositol-3-kinase (PI3K) and the catalytic activity of the p110 subunit of 
PI3K. In addition, to promote PI3K activation, IRS recruits Grb2 to allow an increased 
Ras/raf-1 signaling pathway. Following, to elicit a proper JAK signaling transduction, 
the phosphorylation of the class of transcription factors known as signal transducers and 
activators of transcription (STATs) is required. The STATs family comprises a group of 
cytoplasmic proteins, involved in several functions, including the regulation of the gene 
expression, cell differentiation, survival and apoptosis. Seven mammalian STATs 
(STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6) have been 
characterized, so far (135). The STAT proteins, containing SH2 and SH3 domains, may 
undergo JAK-mediated phosphorylation in a tyrosine residue. Following cytokine 
interaction with receptor and triggering of the JAK-mediated signaling pathway, STATs 
may interact with the cytokine-receptor complex by binding via their SH2 domain to the 
phosphotyrosine of the cytokine receptor chain. In addition, following STATs 
phosphorylation, homo- or hetero-dimerization occurs, by binding of the SH2 domain of 
one STAT molecule to the phosphotyrosine of the second STAT. The specificity of the 
response to cytokines is largely dependent on the particular combination of STATs 
recruited by the different signal-transducing chains of the cytokine receptor. The 
differences in the STATs binding residues of the various cytokine receptors result in 
recruitment of specific STATs. The dimerization of STATs induces translocation of the 
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proteins into the nucleus, where they bind to consensus sequences in the enhancer 
elements of the promoter regions of target genes, leading to gene transcription. 
 A potential role of c in GH-R signaling has been proposed on the basis of the 
impairment of various GH-induced events in c deficient conditions. First, the signal 
transduction properties of GH-R in B-cell lines from X-SCID patients, following GH 
stimulation, is abnormal, in that GH stimulation fails to induce phosphorylation on 
tyrosine residues of several proteins, including STAT5 molecule (136). Previously, it 
has been reported on a patient affected with X-SCID, short stature and peripheral GH 
hypo-responsiveness, an abnormal protein phosphorylation that normally occurs 
following GH-R stimulation. Of note, in this patient the immunological reconstitution 
through bone marrow transplantation paralleled the restoring of GH-R functionality, 
which resulted in a normal production of Insuline Growth Factor-I (IGF-I). GH is an 
important regulator of somatic growth, cellular metabolism, fertility and immune 
function. GH-R consists of a transmembrane protein that contains two motifs and an 
extracellular domain (137). It remains to be further elucidated whether the c 
involvement is required for the expression of the biologic effects of GH and its 
intermediate molecules on cell growth in either physiological or pathogenic conditions. 
 The ability of c to regulate cell cycle progression has been long debated. The 
gene therapy trials have been proved as an efficace alternative approach to cure X-SCID 
patients carrying mutations of c, but the lymphoproliferation documented in 5 out of 20 
patients enrolled into the two different trials (138),  suggested that retroviral insertional 
mutagenesis could occur and play a role in oncogenetic transformation. In 2 cases it was 
associated with an insertional mutagenesis in LMO2 oncogene (139). Of note, 
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lymphoproliferation event has not been observed in gene therapy trials for SCID due to 
ADA deficiency (140), raising the possibility that c could be oncogenic per se. 
In keeping with this hypothesis, overexpression of c transduced through a lentiviral 
vector into stem cells in murine model of X-SCID led to T-cell lymphomas and thymic 
hyperplasia in a third of the cases. Intriguingly, no common integration site was found 
between the mice, which developed T-cell lymphomas. In these mice, differently from 
humans treated with gene therapy for X-SCID, the expression levels of the protein was 
elevated, thus implying that the amount of the protein may be crucial for the c control 
of cell cycle. These results suggest that insertional mutagenesis may not be the only 
cause of leukemogenesis and that the expression levels of c could influence the cell 
cycle progression directly or its effect being mediated by cytokines signaling pathway.  
On the light of the previous observations, to define an intrinsic mitogenic 
property of c dependent on the amount of the protein, we used in vitro cellular models 
containing different amounts of c. In particular, EBV-transformed B-cells (BCLs) from 
normal subjects, cells transduced with lipid vector containing non-targeting short 
interfering RNA (siRNA), BCLs transduced with siRNA to knockdown c expression 
and BCLs from X-SCID patients were used. Our results indicate that silencing of c 
induces a substantial decrease of protein amount in BCLs, demonstrating a direct 
involvement of c in self-sufficient growth of BCLs in a concentration dependent 
manner. We, also, found that the amount of constitutively activated JAK3 parallels the 
extent of c expression. This finding is intriguing, in that constitutively active or 
hyperactive JAK proteins have crucial roles in hematopoietic malignancies, by 
promoting oncogenic transformation (141). In particular, JAK overexpression can be 
considered as one of the main biologic events leading to the constitutive activation of 
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the JAK/STAT pathway that contributes to oncogenesis. In lymphoid cells, the 
involvement of the JAK/STAT pathway in several cellular processes, such as 
proliferation and protection from apoptosis, has also been well documented (142). We 
found that c silencing also inhibits GH-induced cell proliferation. In this context, it is 
known that the activation of JAKs and STATs represents a prominent biochemical event 
during GH-dependent proliferation of lymphoid cell lines and STAT5 is considered a 
transforming agent in lymphoma and other cell types (143), therefore we found that the 
reduction of c amount also inhibits STAT5 activation and its subsequent nuclear 
translocation, which follows GH-R perturbation. Of note, it should be mentioned that 
experimental studies document a role for GH in the initiation and/or promotion of 
tumorigenesis, raising the possibility that patients treated with GH might be at increased 
risk of cancer (144). Moreover, a putative role of GH as a cofactor in tumor growth is 
plausible, since several carcinomas express GH-R (145). In animal models, GH increase 
the incidence of leukemia and solid tumors, and in humans, at supraphysiological doses, 
it can promote lymphoproliferative events (146). In conclusion, these data demonstrate 
a direct relationship between the amount of c expression and its role in cell cycle 
progression. These data add new evidence for a possible intrinsic mitogenic role of c 
related to its cellular amount. This biologic effect could be direct, thus related to the 
molecule per se, or indirect and mediated by the participation to cytokine-receptors 
signaling.  



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2.2. The c promotes cell cycle progression and survival in human continuous 
malignant cell lines  
Tumor cells exhibit the aberrant ability to proliferative without control due to mutations 
affecting genes involved in cell cycle progression, a tightly regulated process (147). 
Moreover, the impairment of apoptosis is a critical step in cancer development (148, 
149), and BCL-2 family proteins play a pivotal role in promoting tumor cell survival 
(150, 151). Cytokines that signal through receptors sharing the c lead to transition into 
the cell cycle and thus proliferation (131). The entry of cells into the cell cycle is 
controlled by an ordered expression/activation of cyclins (152). In addition IL-2R, 
through c, appears to activate a variety of downstream signaling pathways that 
converge on the regulation of Bcl-2, including PI3K and MAPK activation and 
transcription of the c-myc gene (153). In turn, c-myc cooperates with STAT5 to induce 
the expression of cyclin D-type and to promote proliferation (154, 155, 156).  
In the light of these observations, we studied  the involvement of c in these important 
biological process crucial for tumor progression and growth, to verify its direct role in 
tumorigenesis. 
To determine whether c deficiency had an effect on cell survival we examined 
BCLs from healthy donors and X-SCID patients. The percentage of live cells was 
determined using trypan blue staining in the absence or presence of anti-Fas to trigger 
programmed cell death. In unstimulated X-SCID BCLs there was an increase in the 
percentage of cell death. Following stimulation with anti-Fas, control and X-SCID 
BCLs showed a higher and comparable degree of cell death. Programmed cell death is 
mainly mediated by activation of several caspases (157). These molecules exist as pro-
forms that are activated by cleavage by the upstream caspase in the cascade (157). In 
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unstimulated X-SCID BCLs the low viability was not a caspase-dependent process, 
since the presence of the cleaved protein was observed only following anti-Fas 
stimulation. Caspase-independent cell death has been attributed to mitochondrial 
damage (158), which can be regulated by Bcl-2 family members (159, 160). Bcl-2 and 
Bcl-XL operate as critical components in a complex network to integrate information 
and make ultimate life/death decisions. Since the c-dependent cytokines promote cell 
survival by up-regulating the antiapoptotic factor Bcl-2 (161) and Bcl-XL (162), the 
expression of Bcl-2 and Bcl-XL in control and X-SCID BCLs was evaluated. In c-
deficient cells, the expression of Bcl-2 and Bcl-XL was greatly decreased as compared 
with the control. These findings indicate that c is required for cell survival and is 
dispensable for Fas induced cell death. Moreover, the evaluation of molecular 
expression of BCL-XL in unstimulated cells through quantitative real-time PCR, 
revealed that in the X-SCID cells, BCL-XL mRNA was 35% of the control. However, 
evidence exists that autophagy can plays an active role in cell death, by contributing to 
cell death in unfavorable settings such as nutrient or growth factors deprivation (163). In 
keeping with this, probably c could have a role in the autophagy process.  
Subsequently, to define whether the effect of c on cell cycle progression is a 
peculiarity of lymphoblastoid cells or a more general phenomenon involved in cell 
growth of malignancies of hematopoietic cell lineages, we evaluated whether c 
expression could interfere in cell cycle progression in neoplastic cells. We first 
examined the expression of the molecule in cell lines obtained from hematopoietic 
tumors, such as Molt-4, Raji, Rj225 and K-562. The protein was expressed 
predominantly in the K-562 and to a lesser extent in the Molt-4, Raji and Rj225 in a 
decreasing order. In X-SCID BCLs, c expression was completely undetectable. The 
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expression of c was also evaluated in primary leukemic samples from patients with 
ALL, by quantitative real-time PCR. IL-2R mRNA levels was greatly increased in 
leukemic cells as compared with the control. Moreover, to determine whether the 
expression levels of c correlated with the self-sufficient growth in malignant cell lines, 
we examined the proliferation activity of cells under serum-deficient conditions. This 
was first evaluated by comparing the CFSE dilution profile, upon trypan blue exclusion 
assay, of several malignant cells. After 5 hours of serum-free culture, some variations in 
the rate of proliferation among the lines were already evident. K-562 had a high 
proliferation rate, compared with the other cell lines, while no proliferation was 
observed in X-SCID BCLs. Moreover, the proliferation of these cell lines was also 
assessed by 3H-thymidine incorporation assay. The data were in keeping with the 
results of CFSE experiments and a statistically significant relationship between c 
expression and spontaneous cell growth was documented in the examined cell lines (R = 
0.98, p < 0.05). 
In the light of these findings, we hypothesized that the inhibition of c 
expression in hematopoietic malignant cell lines might have a direct effect on 
proliferation of these cells. Short interfering RNA (siRNA) was used to knockdown the 
molecule in these cell lines. Efficiency and specificity of targeted siRNA sequences 
were confirmed by Western Blot analysis on total lysates and quantitative real-time 
PCR on mRNA. The results of western blot assay revealed that at 96 hours following 
the transfection, cells transduced with siR had less c protein than the correspondent 
cells transduced with the control negative siRNA. In addition, a decrease of the IL-2R
mRNA was observed in all cell lines, revealing a knockdown efficiency of 
approximately 85%. In X-SCID cells, IL-2R mRNA was undetectable. Moreover, c 
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knockdown led to a significant decrease of proliferation. In particular, c-silencing 
reduced cell proliferation of Rj225, K-562, Molt-4 and Raji, as compared with control 
siRNA cells. Taken together, these data confirm that c plays a key role in the 
proliferation of these malignant cell lines.  
Alterations in cell cycle machinery, mainly in the regulation of G1/S phase, are known 
to be associated with the development of solid tumors as well as hematological 
malignant diseases (164). To examine the mechanisms by which c regulates cell cycle 
progression, we examined whether different amounts of the molecule were able to 
influence the transcription of genes selectively involved in cell cycle. Of note, cyclins 
are the key regulators of cell cycle progression (152). In particular, during the G0 to G1 
phase transition, cyclins D1, D2 and D3 are the first molecules to be induced. Cyclin A2 
gets activated during the transition from G1 to S phase and B type cyclins are detected 
during G2 exit and mitosis phase (165). Namely, cyclins A2 and B1 have been 
implicated in the pathogenesis of cancer and are overexpressed in several tumors (166, 
167). Evidence indicates that these cyclins are key components of the cell-cycle 
machinery (168) and, in particular, cyclin A is expressed at high levels in hematopoietic 
stem cells and is essential for their proliferation (169). In our study, we observed that 
the expression of A2 and B1 cyclins strongly paralleled the proliferative capability of 
malignant cell lines. Interestingly, a positive correlation between the amount of c and 
the expression of cyclins A2 and B1 was also found. Taken together these data indicate 
that the higher is the rate proliferation of a certain cell line the higher is the expression 
of both c and cyclins A2 and B1, thus confirming their involvement in the process in a 
concentration dependent fashion. We also found an increased expression of all D-type 
cyclins in those cell lines that proliferated mostly, K-562 and Molt-4, whereas they were 


not expressed in the other cell lines, but D1 found in Rj225. D-type cyclins are strongly 
expressed in many malignancies. Overexpression of cyclin D1 protein was documented 
in many forms of cancer, including breast cancer (170), while overexpression of cyclin 
D2 was noted in a wide range of B cell malignancies, such as B cell chronic 
lymphocytic leukemia (171). Like the other D cyclins, cyclin D3 is rearranged and the 
protein is overexpressed in several human lymphoid malignancies. It was documented 
that knockdown of cyclin D3 inhibits the proliferation of acute lymphoblastic leukemia 
cells (172). However, while A and B type cyclins seem to be vital and necessary 
components of cell cycle progression (169), D-type cyclins may be dispensable for 
proliferation under certain circumstances, in that different cell types are sensitive to 
cyclin D knockdown at a different extent (173). This would suggest that they regulate 
cell cycle in a cell-type specific manner and that there are alternative mechanisms 
allowing cell cycle progression in a cyclin D-independent fashion (173). Anyway, a 
critical role for oncogenic transformation of D-type cyclins is a well established feature. 
In conclusion, these data indicate that c is strongly implicated in cell cycle progression 
of hematopoietic malignancies in a similar fashion to the role played in control 
lymphoblastoid cells, as previously described. This biologic effect is strictly dependent 
on the expression level of the molecule and can be abolished by gene knockdown. Of 
note, a direct correlation between the amount of c expression and the proliferative 
capability of the malignant cell lines and the regulatory elements of cell cycle 
progression, A and B cyclins, was found, implying the direct involvement of the 
molecule in this biological process.  
These data have been published as Article on International Immunology, for the 
manuscript see below. 
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2.3. c over-expression in B-precursor acute lymphoblastic leukemia primary cell 
lines from pediatric patients: implication in leukemia cell cycle progression and 
survival. 
In our previous studies, we observed that c exerts a role in either spontaneous or GH-
induced cell cycle progression, depending on the amount of the protein expression 
(174). Moreover, we documented an over-expression of c protein in continuous 
malignant hematopoietic cell lines, and a direct correlation between its expression and 
spontaneous cell growth. In addition, an increased expression of all D-type cyclins and a 
direct correlation between the amount of c and cyclins A2 and B1 expression was 
noted, thus implying a critical regulatory role of c on cell proliferation of continuous 
malignant hematopoietic cells (175). 
 Of note, it is well known that c-receptors play a role in T-cell development and 
function, Under physiological circumstances, and in T-cell Acute Lymphoblastic 
Leukemia (T-ALL) leukemogenesis (176, 177).
 In order to evaluate whether c-receptors are involved in biology of specific type 
of leukemia, and not only in T-ALL, analyzed the c expression profile and c-signaling 
in different types of leukemia. We evaluated the c expression in c primary cells of 
Chronic Myeloid Leukemia (CML), Acute Myeloid Leukemia (AML), B-precursor 
Acute Lymphoblastic Leukemia (B-pre ALL), and T-ALL. We also investigated the 
potential mechanisms by which c exerts its role in leukemia development and 
progression. 
Particularly, we evaluated the expression levels of IL-2R mRNA in primary cells 
derived from bone marrow of 39 newly diagnosed patients with CML, AML, B-pre 
ALL and T-ALL, and control, by performing quantitative Real-Time PCR. We selected 
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only newly diagnosed patients to avoid interpretation bias due to use of 
chemotherapeutic agents. As show in Figure 7A, IL-2R mRNA expression was 
increased in leukemic cells (mean + SE =1,74 + 0,21) as compared with the control. In 
addition, IL-2R was predominantly expressed in lymphoblastic leukemia cells (mean +
SE =2,62 + 0,4) (Figure 7B). 

  
Figure 7: IL2R mRNA expression was increased in leukemia cells. Total RNA from leukemic cells 
and controls was extracted and reverse transcribed. The expression levels of IL2GR were analyzed by 
qRT-PCR in leukemia cells from AML, CML, ALL patients and controls. (B)  IL2GR mRNA amount 
was mainly increased in ALL cells. The relative gene expression is a ratio IL2R/ -actin fold change.  
Each histogram represents the mean + SE. 
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c-signaling cytokines play a central role in T-cell development and in the 
mitogenic potential of primary T-ALL cells (176), suggesting the implication of c-
signaling in this leukemia subtype. Differently from what expected, we found a higher 
expression of IL-2R mRNA in B-pre ALL (mean + SE = 2,92 + 0.5) than in T-ALL 
cells (mean + SE = 1,80 + 0,3 ) (Figure 8). These data suggest a still unappreciated role 
of c in B-pre ALL cells. 
Figure 8: IL2R mRNA expression was higher expression in B-pre ALL than in T-ALL cells. The 
expression levels of IL2GR were analyzed by qRT-PCR. The relative gene expression is a ratio IL2R/ -
actin fold change.  Each histogram represents the mean + SE. 
The master regulator proteins of cell cycle progression are the cyclin-cdk complexes, an 
evolutionarily conserved family of proline-dependent serine/threonine kinases (178).   
 In ALL abnormal expression and function of cell cycle proteins has already been 
documented (179), and, in particular, in B-cell malignancies of D-type cyclins (180) 
under control of PI3-AKT signaling pathways, the latter being, in turn, regulated by c. 
In keeping with this, we investigated the potential regulation of cell cycle progression 
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process promoted by c in B-pre ALL cells, by evaluating expression pattern of D-type 
cyclins through Real-Time PCR. 
 The results showed that D-type cyclins were expressed at higher extent in B-pre 
ALL cells than controls, as shown in figure 3. In particular, all the three cyclins were 
over-expressed in the B-pre ALL (D1 cyclin:  mean  + SE = 21.90 + 2.8; D2 cyclin: 
mean +  SE = 5.18 + 0.80); D3 cyclin mean + SE = 3.22 + 0.61) (Figure 9).   
Figure 9: D1, D2 and D3 cyclins expression levels were increased in B-pre ALL cells. Analysis of D-
type cyclins expression using qRT-PCR revealed up-regulation of all D cyclins. The mRNA levels were 
expressed relative to -actin expression levels.  Each histogram represents the mean + SE. 
We next correlated the expression levels of cyclins D1, D2, D3 with c. As 
shown in Figure 4, a direct correlation between c and cyclins D2 (R = 0.82) and D3 (R 
= 0.76) expression was found, while no correlation between c expression and cyclin 
D1 was observed (Figure 10).  
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Figure 10: Relationship between IL2R and cyclins D1, D2 , D3 expression levels. A direct 
positive correlation between IL2R and cyclins D2 and D3 was found, as demonstrate by value 
of Pearson correlation coefficient (cyclin D2: P = 0.82; cyclin D3: P = 0.76). Any correlation 
between IL2R and cyclins D1 was found. 
Cancer development and progression mainly relies on the ability of tumor cells 
to escape apoptosis more than their normal counterparts (181). Apoptosis is regulated 
by BCL-2 family members, including  BCL-2, BCL-XL, BAX, BAD (182). In keeping 
with this, an abnormal expression or function of BCL-2 family proteins has been well 
documented in human cancer, leading to programmed cell death evasion, and 
chemotherapy resistance (183). Noteworthy, c is also implicated in regulating genes 
involved in this biological process through the activation of PI3-K/AKT signaling 
pathway (184). 
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 To investigate the mechanisms by which c promotes survival in B-pre ALL 
leukemic cells, we evaluated the expression level of the anti-apoptotic BCL-XL by 
quantitative real-time PCR. We observed that in primary B-pre ALL leukemic cells, 
BCL-XL mRNA was 57% than control (mean + SE = 0.57 + 0.12) (Figure 11), thus 
suggesting the presence of alternative mechanisms of the pro-survival effect of c. 
 Recent evidence suggests that autophagy favours cell survival in response to 
multiple stresses, including hypoxia, nutrient deprivation, and other events occurring in 
the primary tumor microenvironment (185, 186, 187). BCL-2 family proteins are also 
involved in autophagy. Indeed, they are able, through their BH3-like domain, to bind 
and inhibit the activation of BECLIN-1, an important mediator of autophagy,  
 Therefore, by using quantitative Real-Time PCR, we observed that the 
expression level of  BECLIN-1 mRNA was increased (mean + SE = 4.73 + 0.71) in B-
pre ALL leukemic cells as compared with the controls (Figure 11), suggesting a 
putative role of c in promoting cell survival in B-pre ALL via autophagy. 
Figure 11: c promote leukemia cell survival via autophagy through the up-regulation of BECLIN-1. 
BCL-XL and BECLIN-1 mRNA expression was analyzed using qRT-PCR. BCL-XL mRNA was 57% of 
controls. BECLIN-1 expression was greatly increased. The mRNA levels were expressed relative to -
actin expression levels. Each histogram represents the mean + SE.
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Western Blot analysis on total lysates obtained from four B-pre ALL patients, 
confirmed the overexpression of BECLIN-1, as compared with normal control (Figure 
12). 
Figure 12: Western Blot analysis revealed over-expression of BECLIN-1 in B-pre ALL, as 
compared with control. Whole cell extracts were prepared from B-pre ALL cells and, BECLIN-1 
expression was determined by western blotting. Densitometric analysis of the above western blot 
was performed by using ImageJ program. 
The regulatory role of a number of cytokines, such as interleukins and colony-
stimulating factors, on the survival, the growth, the differentiation and the apoptosis in 
leukemic cells, both in vitro and in vivo, has been documented (188). Of note, by using 
of knock-out strategy or through the neutralization of cytokines c-receptors, the 



clinical implication of c-dependent signaling has been shown, suggesting that the 
increasing or decreasing of this cascade could be helpful in cancer treatment (131). 
Our results showed that IL2RG was over-expressed in leukemia cells, as compared with 
controls. In particular, we observed that IL2RG mRNA was mainly increased in ALL 
cells. Moreover, we found a predominant up-regulation of  IL2RG expression levels in 
B-pre ALL cells, differently from what expect, because it is well documented the role of 
c-signaling cascade in physiological T-cell development and evidence of involvement 
of c in biology of T-ALL are available (176). Our data demonstrate, for the first time, a 
selective over-expression of IL2RG mRNA in B-pre ALL cells, suggesting a specific 
role of molecule in this leukemia type.  
 Tumor cells exhibit the aberrant ability to proliferative without control due to 
mutations affecting genes involved in cell cycle progression, a tightly regulated process 
(146). The passage through the early G1 and late G1 phase of cell cyle represents a 
critic check-point that irreversibly directs the cells to undergo one cell division (189). 
D-type cyclins are important regulators of this process (190) and their abnormal 
activation or overexpression contribute to pathogenesis of lymphoproliferation (191). 
The overexpresssion of D-type cyclins in B-cell malignancies has been reported (192). 
In addition, in ALL alterations in cyclins D1, D2 and D3 have been documented (193, 
194, 195). Eventually, it has been shown that activation of cyclin D-type expression is 
dependent upon induction of PI 3-kinase/Akt kinase, an important signaling pathways 
downstream c. In our study, we observed that cyclins D1, D2, D3 mRNA expression 
levels were up-regulated in B-pre ALL, as compared with controls. In particular, cyclins 
D1 mRNA was mainly increased. Interestingly, a direct positive correlation between the 
amount of c and the expression of cyclins D2 and D3 was also found. These data 
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demonstrate not yet documented role of c in promoting cell cycle progression of B-pre 
ALL cells through up-regulation of cyclins D2 and D3 expression.  
 The impairment of apoptosis is a critical step in cancer development (148), and 
BCL-2 family proteins play a pivotal role in promoting tumor cell survival (150). It has 
been documented that BCL-XL protein is expressed at high levels in childhood ALL 
(196, 197). Of note, the c signaling pathway leads to selective induction of anti-
apoptotic (Bcl-2 and Bcl-xL) gene expression (162). Differently from what expect, we 
found a reduced mRNA BCL-XL level, as compared with controls. This finding 
suggested that B-pre ALL cells, over-expressing c, are able to escape cell death 
through alternative mechanisms. 
The high proliferation rate of cancer cells requires continuous source of energy 
and nutrient, but the tumor microenvironment is not able to supply these essential need 
for cancer cell survival (198). Under these conditions, the cancer cells undergo a 
shortage of nutrients, thus activating alternative metabolic processes to escape this 
stress and maintain their survival. Of note, several studies reported on a critical role of 
autophagy in protecting cells against a shortage of nutrients, through removal and 
recycling of damaged molecules and organelles, but the exact molecular and 
biochemical mechanism by which cancer cells obtain energy sources in condition of 
lack of external nutrients remains to be elucidate (199, 200). However, evidence 
indicates that the predominant role of autophagy in cancer cells is to confer stress 
tolerance, which allows tumor cell survival (201). 
As for speculated wheatear autophagy activation occurred in B-pre ALL cells, 
we evaluated BECLIN-1 mRNA levels and protein amount in B-pre ALL cells and we 
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found a prominent up-regulation of BECN-1 mRNA levels and protein expression in B-
pre ALL cells, as compared with controls, which suggested autophagy activation..  
Beclin-1, a part of a class III phosphatidylinositol-3-kinase (PI(3)K) complex, 
participates in autophagosome nucleation (202). Beclin-1 is activated by a number of 
proteins (AMBRA1, UVRAG and Bif-1) (203, 204, 205), promoting the activation of 
the PI(3)K protein (Vps34) and the formation of autophagosomes, while its autophagy-
promoting ability is suppressed by antiapoptotic Bcl-2 family members through direct 
binding of BH3-domain-only. 
Of note, the decreased expression of BCL-XL in our leukemic cells, and thus the 
absence of inhibitory effect exerted by this protein on BECN-1, consistent with up-
regulation of BECN-1 expression, supported our hypothesis of autophagy activation. 
In conclusion, we documented for the first time a selective up-regulation of 
IL2RG expression in B-pre ALL cells. Moreover, we demonstrated a direct correlation 
between mRNA levels of IL2RG and cyclins D2 and D3, thus implying a role of c in 
promoting cell cycle progression in B-pre ALL cells by transcriptional regulation of 
these genes. Eventually, we reported on the regulation of B-pre ALL cells survival 
through the activation of autophagy, as suggested by BECN-1 increased expression, 
even though additional evidence of occurrence of this process as well as the 
characterization of the role of c in autophagic cell survival have to be provided. 
The identification of critical role of c in pathophysiology should contribute to develop 
more innovative and effective therapies, aimed to inhibit proliferative and pro-survival 
effects activated by c-receptors.
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2.4. c transducing element as a functional link between endocrine and immune 
system. 
Immune and endocrine systems participate to an integrated network of soluble 
mediators that communicate and coordinate responsive cells to achieve effector 
functions in an appropriate fashion (139). Several evidences demonstrate the existence 
of a previously unappreciated relationship between distinct elements, such as GH-R and 
c and their signaling pathways. Crosstalk between receptor signaling systems is now 
emerging as an important and exciting area of signaling research. The impairment of 
various GH-induced events in c deficiencies suggests a potential interaction between 
GH-R pathways and c, indicating a further functional link between endocrine and 
immune system with potential implication of the molecule in the cell cycle progression 
and control. The existence of shared molecular mechanisms of transduction between 
immune and endocrine systems is well documented in several autoimmune disorders 
characterized by both endocrine and immune features (206, 207, 208). GH-R pathways 
and c interaction leads to the activation and intranuclear translocation of STAT5b 
protein. The signals mediated by STATs generally play a central role in the control of 
important cellular events such as cell proliferation, differentiation and apoptosis (71), 
even though the overall role of the STAT molecules in GH-R signal transduction has 
not been fully elucidated. The overall signal transduction properties of GH-R in X-
SCID patients and control BCLs following GH stimulation, have been recently 
elucidated. In particular, after GH stimulation no phosphorylation of STAT5 protein 
was observed in c negative patients cell lines in contrast to the control cells, in which a 
prompt activation of STAT5 occurred. Of note, reconstitution of XSCID cells with WT 
c gene corrected the functional and biochemical abnormalities resulting in an 


appropriate nuclear translocation of STAT5. These findings strongly support an 
essential role of c in GH-R signaling. Of note, a colocalization of GH-R and c has 
been documented. Even though a physical interaction between the two proteins may be 
possible, any physical association has not yet been documented (136). Currently, studies 
are ongoing to identify potential physical interactions between the two proteins. 
Moreover, evidence suggests that both GH-induced and spontaneous cell cycle 
progression and cell growth are strongly dependent on c expression. Whether the 
participation of c to the GH-R confers some additional properties to the receptor in 
hematopoietic cell differentiation and functioning remains to be elucidated. 
The evidence of this relationship have been published as Review on Current Signal 
Transduction Therapy, for the manuscript see below. 
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2.5. Conclusive remarks 
Immune and endocrine systems participate to an integrated network of soluble 
mediators that communicate and coordinate responsive cells to achieve effector 
functions in an appropriate fashion (139). Evidence documented that both GH-induced 
and spontaneous cell cycle progression and cell growth are strongly dependent on c 
expression (184), suggesting the interplay between endocrine and immune system and 
the main role of c to regulate cell proliferation and growth. 
Alterations of the IL2RG gene leads to X-linked Severe Combined Immunodeficiency 
(X-SCID), which is characterized by an absence of T cells and natural killer cells. 
Patients with X-SCID have a normal number of B cells but these are non-functional. 
Gene therapy trials, as new therapeutic approach for X-SCID, have been performed 
leading to immunological reconstitution but, unfortunately, the occurrence of leukemia 
was documented in few patients (139). In 2 cases it was associated with an insertional 
mutagenesis in LMO2 oncogene. In mice, it has been reported that IL2RG cooperates 
with LMO2 in inducing hematopoietic tumors (210). Of note, no clonal 
lymphoproliferation has been reported, in patients receiving gene therapy for ADA 
deficiency, despite the integration sites near LMO2 (140). Moreover,  overexpression of 
c, in X-SCID mice, led to T-cell lymphomas and thymic hyperplasia with no common 
integration site documented. These results suggested that insertional mutagenesis was 
not the only cause of leukemogenesis, raising the possibility that IL2RG is oncogenic 
per se.   
In this context, we demonstrated that c exerts a role in either spontaneous or GH-
induced cell cycle progression, and this regulatory effect depends on the amount of 
protein expression (174). Moreover, we documented an over-expression of c protein in 
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continuous malignant hematopoietic cell lines, and a directly correlation between the 
amount of molecule with spontaneous cell growth was found. In addition, an increased 
expression of all D-type cyclins and a direct correlation between the amount of c and 
cyclins A2 and B1 expression was documented, thus implying a critical regulatory role 
of c on cell proliferation of continuous malignant hematopoietic cells (175). 
Recently, we found a predominant and selective up-regulation of  IL2RG expression 
levels in B-pre ALL cells, differently from what expect because it is well documented 
the role of c-signaling cascade in physiological T-cell development and evidence of 
involvement of c in biology of T-ALL are available (176). Moreover, exploring the 
potential mechanism by which c regulates leukemia proliferation and survival in B-pre 
ALL cells, we observed that the c promoted cell cycle progression through the 
upregulation of D-type cyclins, while it allowed cell survival via autophagy, as 
suggested by the up-regulation of BECLIN-1 in B-pre ALL cells. 
The new knowledge on the molecular basis of leukemogenesis will allow the 
definition of new scenarios either to identify novel prognostic biomarkers or to develop 
new therapeutic strategies for human hematological malignancies. Currently, several 
studies exploring the role of several genes and proteins involved in leukemogenesis are 
available. The results came out from our studies will give a great contribution in this 
field by unraveling still unidentified mechanisms involved in the pathogenesis of 
leukemia and potential novel clinical implications. In particular, the evidence that c 
plays a role in the growth, cell cycle progression and cell proliferation in primary 
malignant cell lines will be useful at identifying specific drugs targeted to the molecule 
that could exert some beneficial effect on the tumor growth and progression of the 
disease through the modulation of the c expression and activation. Moreover, the 
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selective up-regulation of c expression in specific subtypes of leukemia could be a 
valuable tool for innovative therapeutic approach for B-pre ALL. 
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CHAPTER III 
“Predisposition to cancer and autoimmunity associated with PIDs” 
Immunedeficiencies are genetic or acquired diseases showing predisposition to severe 
infections, but also, in certain circumstances, autoimmunity and cancer, caused to 
abnormal functionality of immune system.  
The increased risk of developing malignancy of patients with 
immunodeficiencies is caused to a defective immunity towards cancer cells. The overall 
risk for children with congenital immunodeficiency to develop tumor is approximately 
4-25% (211). The type of malignancy is highly dependent on the primary 
immunodeficiency, the age of the patient and probably viral infection, suggesting that 
different pathogenetic mechanisms are implicated in each case. Of note, non-Hodgkin’s 
lymphomas predominate (60% of cases) (211). Nevertheless, only a few studies 
regarding the incidence of malignancy in primary immunedeficiencies, the 
histopathological types and prognosis are so far available. It has been documented that 
the median age of diagnosis is 7.1 years with a male predominance, due to an increased 
frequency of X-linked disorders. Moreover, it has been shown that the diseases more 
often associated with tumor were CVID, WAS, A-T and SCID (212). 
The immune system has the peculiar ability to monitor and control infections 
from non-self pathogens while maintaining tolerance to self-antigens. The establishment 
and maintenance of  the mechanism self-tolerance is a necessary ability of adaptive 
immunity. Breakdown of either central or peripheral tolerance can lead to 
autoimmunity. In PIDs the occurrence of autoimmunity represents a failure of immune 
system in responding to non-self pathogens and simultaneously a vigorous reaction to 
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self-antigens. Of note, studies of several monogenic human immune disorders and 
animal models have shown that the impaired functionality of the immune system can 
provoke breakdown of central and peripheral tolerance and consequently the 
development of autoimmune disease.
3.1. Ataxia telangiectasia 
Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder characterized by 
progressive neurological dysfunction, especially affecting the cerebellum, 
oculocutaneous telangiectasia, immunodeficiency, high incidence of neoplasms and 
hypersensitivity to ionizing radiations (213, 214). A-T is associated with mutations in 
the ATM gene, spanning 150 kb of genomic DNA and encoding for a 370-kDa 
serine/threonine (215). ATM plays a key role in the control of various cellular processes 
such as DNA repair, cell cycle progression, gene transcription, protein synthesis and 
degradation, and apoptosis. A-T may be considered a prototype of the DNA repair 
defect syndromes, since the disease shows the typical consequences of defects in the 
DNA damage response (DDR): degeneration of specific tissue affecting particularly the 
nervous and immune systems, chromosomal instability, and sensitivity to specific 
DNA-damaging agents. However, the neuronal degeneration in A-T is only partially 
due to defective DNA damage response DDR (216).  In fact, it has been proposed a new 
role of ATM in maintaining the reducing power of the cellular environment, acting as 
redox sendor. Furthermore, recent studies highlight the role of ATM in modulating 
mitochondrial homeostasis. Of note, a fraction of ATM localizes to the mitochondria 
and can be activated by mitochondrial dysfunction in the absence of DNA damage 
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(217). Since the high rate of transcription and translation in neurons creates a stressful 
environment, neuronal genomic and mitochondrial DNA are constantly attacked, 
suggesting that the mitochondrial dysfunction and the increase in mitochondrial reactive 
oxygen species may contribute to the A-T phenotype.
To date, only supportive care aimed to halt the progressive neurodegeneration is 
available for the treatment. Recently, an improvement of neurological signs during 
short-term treatment with oral betamethasone has been reported. In A-T, and in several 
neurodegenerative disorders, an inappropriate apoptosis seems to play an important 
pathogenic role. In this contest, studies showed that Glucocorticoids (GCs) were able to 
enhance apoptosis in inflammatory and immune cells, whereas, at the same, time they 
seem to protect tissues in which the inflammation takes place (218, 219). GCs were 
capable to diffusing into the Central Nervous System (CNS) by crossing the blood-brain 
barrier (BBB), where they exerted effects on the suppression of inflammation or as 
antioxidant and protected post-mitotic neurons from apoptosis. Eventually, GCs 
potentially also played a role in modulating synaptic plasticity, reducing the impact of 
disability (220).  
However, the molecular and biochemical mechanisms by which the steroid 
produces such effects have not yet been elucidated. A better understanding of the 
mechanisms of action of GCs in the brain is needed, because in A-T during the initial 
phase of cell loss, the neurological impairment may be rescued by interfering the 
biochemical pathways. This would open a new window of intervention in this so far 
non-curable disease. 
These data have been published as Review on European Journal of Neurology, for the 
manuscript see below. 
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3.2. Autoimmunity and PIDs: a focus on APECED 
Tolerance represents a state of immunologic non-responsiveness in the presence of a 
particular antigen. In this context, T-cell tolerance is crucial for the generation of a 
proper T-cell repertoire, able to respond to a huge number of foreign antigens, but 
preventing autoimmune reactions. The generation of appropriate self-tolerant the T-cell 
repertoire is exerted at two levels: (1) central tolerance (development and selection of T-
cells in the thymus) and (2) peripheral tolerance (deletion, anergy of mature T-cells in 
lymphoid and non-lymphoid organs) (221). The intrathymic central tolerance is the 
mechanism by which T cells binding self-antigenswith high avidity, potentially 
autoreactive lymphocytes, are eliminated through the negative selectionprocess (221, 
222, 223, 224). Autoreactive lymphocytes that have escaped negative selection are 
deleted in the periphery through the mechanisms of the peripheral tolerance (221).  
Within the thymicmedulla negative selection ismediated bymTECs andmedullary DCs 
(mDCs).Mature mTECs display a peculiar phenotype, characterized by the high surface 
expression of CD40, CD80, CD86, andMHC class II, which favors an efficient 
thymocyte deletion. The prominent process in inducing the negative selection is 
represented by the broad expression of tissue-specific antigens (TSA).This high 
expression by mTECs of genes encoding TSA, normally found in the periphery, is 
driven by the transcription factor autoimmune regulator (AIRE) (222, 223, 224, 225). 
These TSA include, among other tissues, proteins restricted to the pancreas, stomach, 
eye, salivary gland, muscle, and thyroid (226, 227, 228, 229). However, AIRE doesn’t 
regulate the expression of all TSA genes by mTECs. Surprisingly, only 1–2% of 
mTECs express a given TSA, making it very difficult to understand how a low number 
of mTECs is able to delete a so huge number of clonotypes (228). It has been 
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hypothesized that during a 4- to 5-day period the high motility of thymocytes allows 
them to make a huge number of interactions with mTECs (230). mDCs have a similar 
role, even though they acquire TSA mostly through the uptake of apoptotic mTECs. 
Alternatively, they migrate from the periphery into the thymus (231).  
Some of the thymocytes that recognize self-MHC-peptide complexes with high 
affinity express Foxp3 and mature as Tregs, which are able to suppress autoreactive T 
cells in the periphery (232, 233). To mature into Tregs, the precursor cell must bind 
self-antigens with high avidity. In the mouse model, it has been shown that strong and 
not weak interactions between TCR and agonist peptide lead to the development of 
Foxp3
+
 Tregs with regulatory properties (234, 235). However, there is evidence 
suggesting 
the involvement of additional factors inthenatural differentiation of Tregs (236). Of 
note, two mechanisms to suppress self-reactive thymocytes have been proposed: 
triggering of co-stimulatory molecules and the activation of Fas signaling pathway. In 
particular, it has been shown that the co-stimulatory molecules such as CD40, CD80, 
and CD86, which are expressed by mTECs and mDCs, play a pivotal role in clonal 
deletion (237, 238). Indeed, exposure of DP thymocytes to anti-TCR monoclonal 
antibody (mAb) fails to induce thymocytes death, but not in the presence of APCs 
(239). In the presence of APCs expressing B7 molecules, a crucial co-stimulatory 
factor, which interacts with thymocyte CD28 receptor, DP thymocytes undergo 
apoptosis using anti-TCR and anti-CD28 mAb in vitro. Furthermore, it has been 
observed in SP thymocyte cultures that the exposure to high concentration of anti-TCR 
mAb is able to induce apoptosis through a high-level TCR signaling in the absence of 
co-stimulation (240). This effect is abolished in Fas-lpr/lpr cells (241), carrying 
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homozygous mutation of Fas, a member of the tumor necrosis factor receptor 
superfamily. Thus, the strong TCR ligation leads to apoptosis in a Fas-dependent 
manner in the absence of costimulatory signals (241). On the contrary, moderate-avidity 
TCR binding requires interactions with co-stimulatory molecules to induce apoptosis 
and, therefore, under these circumstances, cell death is induced by a Fas-independent 
mechanism. 
The alteration of this orchestrated process leads to autoimmune diseases. Particularly, 
the prototype of a genetically determined failure of central tolerance leading to 
autoimmunity is APECED, caused by mutations in AIRE gene. APECED is a rare 
disease (OMIM 240300) (242) with a complex clinical phenotype discovered over 
decades (243). Patients with APECED have a highly variable pattern of destructive 
autoimmune reactions toward different endocrine and nonendocrine organs mainly 
involving parathyroid glands, adrenal cortex, gonads, pancreatic beta cells, gastric 
parietal cells, and thyroid gland. Moreover, ectodermal abnormalities are frequently 
present. The main ectodermal manifestations in APECED are dental enamel hypoplasia, 
pitted nail dystrophy, and alopecia. Keratopathy, vitiligo, and calcification of the 
tympanic membranes can also be described. Furthermore, autoimmunity in APECED 
may involve the gastrointestinal system, leading to autoimmune gastritis, 
malabsorption, and autoimmune hepatitis (244). The classical clinical diagnosis is 
primarily based on the presence of two of the three most common clinical features: 
chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH), and 
Addison disease (AD) (245).The presence of only one component is sufficient for the 
diagnosis if a sibling is affected (246). Autoantibodies for type 1 IFN (IFN-	 and IFN-
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) may be considered as a specific and sensitive diagnostic tool for APECED (247). Of 
note, the APECED varies in the severity and number of disease components.  
So far, over 60 different mutations of the AIRE gene have been documented in 
APECED patients (248). Some different mutations have been found to be peculiar 
of specific geographic areas. 
However, the great variability of APECED phenotype implies the participation 
of several disease-modifying genes and environmental factors to the disease phenotypic 
expression. In the near future, total exome sequencing could be a good perspective from 
which to analyze genetic variations involved in inheritance and clinical expression of 
autoimmune diseases. 
These findings have been published as Review on International Reviews of Immunology 
and Expert Review Clinical Immunology, for the manuscript see below. 
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3.3. Conclusive remarks 
The abnormal functionality of the immune system leads to immunedeficiencies, genetic 
or acquired diseases showing predisposition to severe infections, which in certain 
circumstances may also cause autoimmunity and cancer. The prototype of PIDs 
associated with predisposition to cancer and autoimmunity are, respectively, A-T and 
APECED diseases. 
A-T is considered a DNA repair defect syndromes, associated to degeneration of 
specific tissue affecting particularly the nervous and immune systems, chromosomal 
instability, and sensitivity to specific DNA-damaging agents. Recently, an improvement 
of neurological signs during short-term treatment with oral betamethasone has been 
reported, even though the molecular and biochemical mechanisms by which the steroid 
produces such effects have not yet been elucidated. A better understanding of the 
mechanisms of action of GCs in the brain is needed and it should open a new window of 
intervention in this so far non-curable disease.  
It is known that the systemic autoimmunity and immunodeficiency can be 
strictly linked. The discovery of genetic diseases caused by alterations of genes 
implicated in the tolerance mechanisms enormously contributed to our understanding of 
the molecular basis of human autoimmune disorders, generally and appropriately 
considered as multifactorial diseases. The paradigm of the genetically determined 
alteration of central tolerance is related to mutations of the AIRE transcription factor. 
This disease gave a huge amount of information on the functional and molecular events 
that lead to the elimination of self-reactive T-cell clones within the thymus. The 
elucidation that TSA are broadly expressed by mTECs also helped in understanding the 
	

mechanism by which autoimmunity may also paradoxically be associated with an 
immunodeficiency status.
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CHAPTER IV 
“Rare Genetic Syndromes involving Immune System” 
4.1. SCID-Like phenotype associated with an inhibitory autoreactive 
immunoglobulin 
The SCIDs, irrespectively of the individual genetic form, show abnormal T cell-related 
functions, thus overall compromising a normal, productive immune response in all 
effector tasks (249). Severe impairment of T-cell function, however, may also be 
acquired and induced by viruses, such as the human immunodefi ciency virus (HIV) 
(250), but no autoreactive anti-lymphocyte antibody capable of inducing a SCID-like 
phenotype has been previously described. 
For the first time, our group described the autoreactive anti-lymphocyte antibody 
capable of inducing a SCID-like phenotype in 3-year-old patient with a phenocopy of 
T
low
 B
+
 NK
+
 -SCID. The patient shows inhibition of normal peripheral mononuclear cell 
(PBMC) proliferation after stimulation with phytohemagglutinin (PHA), which could be 
due to inhibitory autoantibody in our patient, as a consequence of hyperimmune 
dysregulation.  
 Importantly, we have documented a novel pathogenetic mechanism due to an 
inhibitory anti-lymphocytic autoantibody in a SCID-like phenotype, resulting in total T-
cell activation deficiency associated with autoimmunity. 
The data have been published as Case Report on Journal of Investigational Allergology 
& Clinical Immunology, for the manuscript see below. 
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4.2. A novel mutation of IL2R associated to an atypical Immunedeficiency 
Interleukin-12 (IL-12) is involved in cellular immune responses against 
intracellular pathogens by promoting the generation of T naive in T helper 1 (Th1) 
cells and by increasing interferon-gamma (IFN-gamma) production from T and 
natural killer (NK) cells. A defective induction of a Th1 response may lead to a 
higher risk of infections, and, in particular, infections due to typical and atypical 
Mycobacteria. We report on the case of a girl with suffering from recurrent 
bronchopneumonia associated with very high serum IgE levels, who exhibited a 
profound impairment of the Th1 generation associated with a novel mutation in 
the exon 5 of the IL-12R 1 gene (R156H). Our data suggest that in children with 
severe and recurrent infections, even in the absence of a mycobacterial infection, 
functional and/or genetic alterations of the molecular mechanisms governing 
Th1/Th2 homeostasis might be responsible for an atypical immunodeficiency and, 
therefore, should be investigated in these patients. 
The data is being published as Clinical Report on American Journal of Medical 
Genetics, for the manuscript see below. 
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4.3. De novo 13q12.3q14.11 deletion involving BRCA2 gene in a patient with AT-
like phenotype.
Deletion of the long arm of chromosome 13 is a rare condition characterized by a wide 
range of clinical features, including developmental delay and intellectual disability, 
growth retardation with microcephaly, hypotonia, trigonocephaly, facial dysmorphism, 
limb defects such as hypoplastic or absent thumbs and anogenital anomalies (251). The 
clinical phenotype varies according to the location and size of the deletion. Involvement 
of the critical band 13q32 causes three major phenotypes (252). Distal deletions are 
closely associated with the more severe phenotypes, whereas proximal deletions cause 
fewer anomalies, but include retinoblastoma (253). Alterations of the ZIC2 gene, which 
maps on the critical 13q32 region, have been associated with holoprosencephaly (HPE) 
(254).  
Our group report on an atypical syndrome, due to a de novo deletion of 
chromosome 13, which leads to a novel clinical phenotype characterized by 
immunodeficiency with elevated IgM levels, mild and transient cerebellar ataxia, 
increased frequency of chromosomal breaks, telangiectasia and freckles associated with 
microcephaly, developmental delay, facial dysmorphisms, skeletal anomalies, and 
spontaneous fractures. Array-comparative genomic hybridization (CGH) defined a 
12Mb deletion on chromosome 13q12.3-q14.11, which includes the BRCA2 gene. 
The data is being published as Clinical Report on American Journal of Medical 
Genetics, for the manuscript see below.?
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4.4. Conclusive remarks 
The description of new clinical phenotype and novel genetic syndrome involving the 
immune system, opens new scenarios in the molecular mechanisms underlying the 
immune response. 
 Our group have documented for the first time a novel pathogenetic mechanism 
due to an inhibitory anti-lymphocytic autoantibody in a SCID-like phenotype, resulting 
in total T-cell activation deficiency associated with autoimmunity. Therefore, we 
reported on severe impairment of T-cell function which was not acquired and induced 
by viruses. 
 Of note, we documented an interesting case of children with severe and recurrent 
infections, even in the absence of a mycobacterial infection, functional and/or genetic 
alterations of the molecular mechanisms governing Th1/Th2 homeostasis might be 
responsible for an atypical immunodeficiency and, therefore, should be investigated in 
these patients. 
 Eventually, we described a novel clinical phenotype characterized by 
immunodeficiency with elevated IgM levels, mild and transient cerebellar ataxia, 
increased frequency of chromosomal breaks, telangiectasia and freckles associated with 
microcephaly, developmental delay, facial dysmorphisms, skeletal anomalies, and 
spontaneous fractures, with the chromosomal deletion 13q12.3–q14.11, which includes 
the BRCA2 gene.  
Taken together, these findings demonstrate that important issues on 
immune system activity and function have to be elucidated. 
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TECHNOLOGIES 
§ Cells and cell cultures 
Cord blood (CB) from the FOXN12/2 fetus was obtained by cordocentesis at 16 weeks 
of gestation. Peripheral Blood Mononuclear cells (PBMC) were obtained from patients 
and healthy donors by Ficoll-Hypaque (Biochrom) density gradient centrifugation. 
Leukemia cells were obtained from the bone marrow of newly diagnosed patients, with 
high leukemia involvement (85-100%), affected by Chronic Myeloid Leukemia (CML), 
Acute Myeloid Leukemia (AML), B-precursor Acute Lymphoblastic Leukemia (B-pre 
ALL) and T-ALL, by using Ficoll-Hypaque (Biochrom) density gradient centrifugation. 
Normal bone marrow cells were obtained from healthy donors and used as control cells, 
through the same procedure.   
Keratinocytes were isolated by incubation of skin fragments in HBSS (Ca2
+
 Mg2
+
 free) 
containing 0.75% sodium bicarbonate, 100 mM HEPES (Gibco) supplemented with 25 
µg/ml Gentamicin with Dispase II (20 mg/ml, Roche). Subsequent removal of 
epidermal sheet with tweezers, followed by incubation for 10 min at 37°C in 0.05% 
Trypsin and 0.5 mM EDTA (Gibco).  Trypsin-EDTA were stopped adding the same 
volume of Fetal Bovine Serum (FBS). Cells were filtered through double layer gauze 
sterilized and then washed with DMEM containing 10% FBS. 5 x 10
6
 keratinocytes 
were plated in 100 mm dish pre-treated with collagen coating solution containing HBSS 
with 100 µg/ml BSA, 20 mM HEPES pH 6.5, 30 ug/ml bovine type I collagen isolated 
from dermis (Nutacon).  Cells were grown in supplemented Keratinocyte-SFM medium 
with 30 µg bovine pituitary extract and 0.2 ng/ml human rEGF (Gibco) and 100 IU/ml 
Penicillin and 100 µg/ml Streptomycin. The cultures were incubated at 37°C in the 
atmosphere supplemented with 5% CO2, with the cell culture media changed daily.  
Fibroblasts were isolated by mincing of dermal skin fragments and were grown in 
Dulbecco’s modified Eagle’s medium (Invitrogen) and 10% FBS (Gibco), 
supplemented with 100 U/ml Penicillin and 100 µg/ml Streptomycin (Invitrogen).  The 
cultures were incubated at 37°C in the atmosphere supplemented with 5% CO2, with the 
cell culture media changed daily. Moreover, keratinocytes and fibroblasts were 
passaged fewer than 5 times before use in experiments. 
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CD34
+ 
hematopoietic stem cells were isolated by incubating 1-2 x 10
8  
PBMCs in 300 l 
of PBE with 100l of CD34 (QBEND 10)-conjugated magnetic beads (Multisort beads, 
Miltenyi Biotec), followed by incubation for 30 min at 4-8°C. After incubation, the cells 
were washed with ice-cold PBE (PBS/0.5% bovine serum albumin/5 mM EDTA) and 
processed through a column placed in a magnetic field and the target cells retained.  
After washing the column thoroughly with ice-cold PBE, the target cells were recovered 
by removing the magnetic field and flushing the column with 1 ml of PBE.  CD34
+ 
cells 
were then labeled with a CD34-FITC conjugated antibody for 15-20 min at room 
temperature. 
B lymphoblastoid cell lines (BCLs) were generated by EBV immortalization of patients 
and healthy donors PBMC using standard procedures.   
The human continuous T-acute lymphoblastic leukemia cell line (Molt-4), the chronic 
myelogenous leukemia cell line (K-562), Burkitt lymphoma cell line and its isogenic 
derivatives (Raji and Rj225) were grown in RPMI-1640 (Lonza, Verviers, Belgium) 
supplemented with 10% fetal bovine serum (FBS; Gibco), 2 mmol/L L-glutammine 
(Gibco), and 50 µg/ml gentamycine (Gibco), and cultured at 37°C, 5% CO2. Serum 
starvation was used to synchronize tumor cells in the G0/G1-phase of the cell cycle.  
The cells were incubated in medium without FBS for 24 hours. In self-sufficient growth 
experiments, cells were cultured in DMEM/F12 (Lonza) without FBS and supplemented 
with 2 mmol/L L-glutammine.   
§ Reprogramming of human fibroblasts and iPSCs culture, cleaning and passage 
Human wild-type skin fibroblasts (600000 total cells) have been reprogrammed by 
introducing 3 episomal vector containing cDNA of human Oct3/4, Sox2, Klf4 and L-
Myc (Figure 6) and by using electroporation.  
Fibroblasts trasfected have been plated on mitomycin C-treated  feeder cells MEFs in a 
six-well plates, with Fibroblasts Medium Culture without Gentamicin. The next day, the 
medium has been replaced with new Fibroblasts Medium Culture enriched with 
Gentamicin. At the 4
th 
day, the medium for primary hES cell culture (hESC medium), 
supplemented with FGF2 (10 ng/ml), SB431542 (2M), PD0325901 (0.5 M),  
Valproate (500 M), has been used. hESCs medium has been replaced every 2 days and 
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the molecule have been added until 14 days after trasfection. Subsequently, the clones 
were culture  
The iPSCs clones have been picked, by cutting around the colonies with a needle 
mounted on 1mL siringe, until 20 days after trasfection. Of note, the first day of the first 
two passage was used Rock-Inhibitor to favor clones attachment. To amplify the 
colonies, they were cut into square pieces of 200µm and they were plated on BJ1-FGF2 
feeder layer. The colonies were cleaned from differentiated parts by cutting with a 
needle and the debris were removed by aspirating the medium culture, which was 
replace with the new one.  After the 5
th
 passage, the clones were cleaned, detached with 
Dispase (1mg/mL) and freeze by using CryoStor
TM
CS10 solution. 
§ Alkaline phosphatase staining  
The culture medium was aspirate from iPS cell culture plates to fix by adding ethanol 
95% just to cover the cells. Following, the plates were washed 3 times with PBS 1X. 
BCIP/NBT substrate solution was added so as to cover the cells, for 10 minutes at 37°C 
5% CO2. The plates were washed 3 times with PBS 1X and dried at RT. 
§ Histology 
Intestine and liver tissue samples from a 16 weeks FOXN1
-
/
-
 fetus or control were 
embedded in OCT compound and snapfrozen in liquid nitrogen or paraffin-embedded. 
The blocks were cut into serial 5-mm sections and mounted onto microscope slides for 
H&E staining and immunohistochemistry analysis. Immunodetections were performed 
by means of a Ventana automat (Ventana Medical Systems).  
§ Immunohistochemistry 
Tissue sections staining was performed on Benchmark XT platform (Ventana Medical 
Systems) with pre-diluted CD34, CD20, CD56, CD3, CD4 (Ventana-Confirm), CD8 
(Cell Marque), 1:40 CD103 (Beckman Coulter, Brea, CA), 1:50 CD45RA (Dako, 
Denmark) and 1:25 CD62L Abs (Abcam, Cambridge, UK). Heat antigen retrieval was 
performed in buffer (CC1, Ventana) following the manufacturer instructions. The slides 
were incubated with primary Abs at 37u for 32 min (CD34, CD20, CD56, CD3, CD4 
and CD8) or for 60 min (CD45RA, CD103, CD62L). Primary Ab was omitted for 
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negative control. Nuclei were counterstained with hematoxylin. The reaction was 
detected by the ultraView Universal DAB Detection Kit, which utilizes a cocktail of 
enzyme labeled secondary Abs that locates the bound primary Ab. The complex is then 
visualized with hydrogen peroxide substrate and 3, 39-diaminobenzidine 
tetrahydrochloride (DAB) chromogen, which produces a dark brown precipitate readily 
detected by light microscopy. Images were acquired by a microscope (DM 2500; Leica, 
Germany) at magnification 200X or 100X. 
§ siRNA transfection 
The validated chemically modiﬁed oligonucleotides used as siRNA for IL2RG or 
random non-silencing nucleotides with no known specificity siRNA, used as negative 
control, were obtained from Invitrogen (Paisley, UK).  These siRNAs were transfected 
at a concentration of 200 pmol/1x10
6
 cells in a six well plate for 96 hours. The 
transfection was performed by the lipid vector Lipofectamine 2000 kit (Invitrogen, 
Paisley, UK), according to the manufacturer’s instructions.  Preliminary experiments 
were performed to establish the silencing efficiency by testing two different 
oligonucleotides obtained from Invitrogen (Paisley, UK). The amount of protein 
expression reduction was calculated as follows: 1- (ODsiRNA x 100 / ODcontrol siRNA). In 
self-sufficient growth experiments, BCLs were cultured in Dulbecco modified Eagle 
medium (DMEM)/F12 without FBS and supplemented with 2 mM/L L-glutamine.
  
§ Proliferative assay 
Cell proliferation was analyzed by the CFSE dilution assay. Cells (1x10
6
) were 
resuspended in 1 ml PBS-10% FBS and labeled with 1.7 M CFSE (Molecular Probes).  
After 2 min in the dark at room temperature, cells were washed in FBS and PBS.  After 
6 hours cells were analyzed on a FACSCalibur flow cytometer using CellQuest 
software (BD Biosciences).  
Cell viability was determined using trypan blue staining.  Cell survival was evaluated 
following stimulation with anti-Fas mAb (400 ng/ml; Upstate) for 6 hours. 
Cell proliferation was also analyzed by the thymidine incorporation assay.  
For the evaluation in vitro of proliferative response to mitogens of PMBC and CBMC, 
cells were stimulated with phytohaemagglutinin (PHA; 8 g/ml), concanavalin A 
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(ConA; 8 g/ml), pokeweed (PWM, 10 g/ml) (Difco Laboratories), phorbol-12-
myristate-13-acetate (PMA; 20 ng/ml) and ionomycin (0.5 mM) (Sigma Chemical Co).  
CD3 cross-linking (CD3 X-L) was performed by precoating tissue culture plates with 1 
and 0.1 ng/ml purified anti-CD3 monoclonal antibody (Ortho Diagnostic).   
Cells were plated in triplicate at 1x10
5
 viable cells/well in 96-well plates (BD 
Biosciences), in 200 l of complete medium for 4 days.  Cultures were pulsed with 0.5 
Ci 
3
H-thymidine for 8 hours before harvesting and the incorporated radioactivity 
measured by scintillation counting.   
In a few experiments complement components were inactivated through heating of 
serum samples at 56° C for 30 min before use.  The percentage of inhibitory activity in 
the sera was calculated from the formula: (cpm of PHA-stimulated cultures containing 
5% tested serum/cpm of PHA-stimulated cultures containing 5% FCS) x 100.  Patients 
and normal IgG were purified using a protein G column according to the vendor’s 
instructions (Pharmacia Biotech). 
§ Reagents, western blot and immuneprecipitation 
The enhanced chemiluminescence (ECL) kit was purchased from Amersham 
Biosciences.  The Abs anti-c, anti-JAK3, anti-beta-actin, anti-Bcl-2, anti-Bcl-XL, anti-
histone 3 (H3), anti-phosphotyrosine, anti-STAT5, anti-STAT4, anti-BECLIN-1 were 
purchased from Santa Cruz Biotechnology.  The Ab anti-caspase 3 was purchased from 
Cell Signaling Technology. Acrylamide and bisacrylamide were obtained from 
Invitrogen.  Prestained molecular mass standards were obtained from Bio-Rad.  Except 
where noted, other reagents were from Sigma-Aldrich.   
Stimulated or unstimulated cells were washed with ice-cold phosphate buffer saline 
(PBS; Cambrex, Charles City, IA) and lysed in 100 l of lysis solution containing 20 
mM Tris (pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride, 1 mM sodium orthovanadatum (Na3VO4), 5 g/ml 
leupeptin and 5 g/ml aprotinin on ice for 45 min.  The cell lysates were stored at -80°C 
until processing.  Proteins were separated on 12% SDS-PAGE.  The membrane was 
then washed three times in wash buffer and incubated 1 h at room temperature or 
overnight at 4°C with the specific Ab. The membrane was then washed three times and 
an appropriate IgG HRP-conjugated secondary Ab was used for the second incubation. 
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After further washings, the membrane was developed with ECL-developing reagents, 
and exposed to x-ray films according to the manufacturer’s instructions (Amersham 
Biosciences).   
For immunoprecipitation, lysates were normalized for either protein content or cell 
number and precleared with protein G agarose beads (Amersham Biosciences).  The 
supernatant was incubated with 2 microg/ml anti-JAK3 or polyclonal serum, followed 
by protein G agarose beads.  The immunoprecipitates were separated on density 
gradient gels, followed by Western blotting.  Proteins were detected using antibody for 
phosphotyrosine.  
Densitometric analysis was performed after background equalization through the 
ImageJ software.    
§ Confocal microscopy 
After appropriate stimulation, as indicated, cells were fixed in 4% paraformaldehyde in 
0.1 M phosphate buffer (pH 7.0) for 30 min at room temperature and centrifuged in a 
Shandon Cytospin III (Histotronix) onto a glass slide and permeabilized by incubation 
in a 0.2% Triton X-100 solution for 20 min.  BCLs were incubated for 1 h at room 
temperature with rabbit anti-STAT5 Ab in PBS containing 1% BSA.  After four 
washings for 5 min in PBS, the cells were incubated for 1 h at room temperature with 
FITC-conjugated donkey anti-rabbit IgG (Pierce) in PBS. After washing in PBS, the 
glass slides were mounted under a coverslip in a 5% glycerol PBS solution. The slides 
were analyzed by laser scanning confocal microscopy using a Zeiss LSM 510 version 
2.8 SP1 Confocal System (Zeiss).  At least 100 cells per condition were analyzed in 
each experiment to determine the rate of STAT5 nuclear translocation. 
Intestine and liver tissue samples were blocked with normal goat serum before staining 
and then treated with 1:50 of PerCP-labeled CD3 (BD Pharmingen, San Diego, CA) and 
1:100 of FITC-labeled CD45RA Abs (BD Pharmingen, San Diego, CA) or 1:50 of PE-
labeled CD4 (Beckman Coulter, Brea, CA) and 1:50 FITC-labeled CD8 (Beckman 
Coulter, Brea, CA) or 1:50 APC-labeled CD3 (Beckman Coulter, Brea, CA) and FITC-
labeled CD7 (Beckman Coulter, Brea, CA). Images were acquired by a confocal 
microscope (LSM 510, Zeiss, Germany). 


§ PCR and quantitative real-time PCR analysis  
Total RNA from leukemic samples and controls was extracted using TRIzol reagent 
(Invitrogen, Carlsbad, CA), according to the manufacturer’s instructions. RNA was 
reverse transcribed by Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany). 
The qPCR reactions were performed in duplicate. The amplification of the cDNAs was 
performed using the SYBR Green and analyzed with the Light Cycler480 (Roche 
Applied Systems, Germany). The primers used are listed in Table 1. Cycling conditions 
comprised an initial denaturation at 94°C for 5 min, a phase of annealing/extension for 
each gene, as follow: 50 cycles at 62°C for 5s  (IL2RG); 40 cycles at 62°C for 7s 
(Cyclin D1); 50 cycles at 62°C for 3 s (Cyclin D2); 40 cycles at 62°C for 7 s (Cyclin 
D3); 40 cycles at 62°C for 7 s (BCL-XL); 45 cycles at 62°C for 5 s (BECLIN-1),  55 
cycles at 62°C for 5sm 35 cycles at 62°C for 20 s (IKAROS, TAL1, SPIB, PTCRA, 
RAG2, CyclinA1 and CyclinB1) and 72°C for 5 min. A dissociation procedure was 
performed to generate a melting curve for confirmation of amplification specificity. The 
relative levels of gene expression are represented as -
Ct=(Ctgene-Ctreference) and the fold 
change in gene expression was calculated by the 2
-

Ct
 method (where Ct is cycle 
threshold), as previously described. 
To evaluate IL-12R2 chain expression, RNA was reverse transcribed into cDNA using 
ExpandTM Reverse transcriptase according to the manufacturer's protocol (Boehringer 
Manneheim).  The cDNA was PCR amplified (94°C, 1 minute; 55°C, 1 minute; 72°C,1 
minute for 30 cycles) using specific primers for IL-12R2: sense primer 
GGAGAGATGAGGGACTGGT and antisense primer TCACCAGCAGCTGTCAGAG.  
To monitor the amount of RNA, -actin mRNA expression was used.  PCR products 
were separated in a 1% agarose gel and viewed after ethidium bromide staining.  
§ Flow cytometry analysis  
At defined time-points (0, 1, 2, 3 and 4 w), the cells cultured on each of the PCL 
construct were extracted from the scaffolds by aspiration of the medium and flushing of 
the matrices.  Cells were exposed to directly-conjugated mouse anti-human monoclonal 
antibodies (mAbs) to asses hematopoietic stem cells with CD34-APC (BD Biosciences), 
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CD45-APC-Cy7 (BD Biosciences), and lymphocyte precursors with CD7-PE 
(Immunological Sciences), CD1a-FITC (DAKO), CD3-PerCP (BD Biosciences), CD4-
PE (BD Biosciences), CD8-PECy7 (Beckman Coulter).  The cells were incubated with 
directly-labelled antibody clones at 4°C in the dark for 30 min, washed and resuspended 
in 100 ml PBS.  The events in the displayed graphs (Figure 4, 5B, 5C) and dot plots 
(5A, 5D, 5E, 5F, 5G) were gated by forward and side scatter to exclude dead cells. For 
analysis of early thymocyte subsets with CD7, CD3, CD4 and CD8 T-cell precursors 
were identified by gating on viable CD45+ cells. Analytical flow cytometry was 
performed using a BD FACS Canto II flow cytometer (BD Biosciences).  Subsequent 
data processing and preparation for presentation was done using BD FACSDiva 
software. 
In flow cytometry of CBMCs, FITC-, phycoerythrin (PE)-, allophyocyanincyanine 7 
(APC-Cy7)-, peridin chlorophyll protein (PerCP)- or PECy7-coupled Abs were used on 
CB toward CD45 (2D1), CD7 (MT701), CD2 (RPA-2.10), CD3 (UCHT1), CD8a (SK-
1), CD8b (2ST8.5H7), CD4 (L200), CD62L (SK11), CD45RA (HI100), CD27 (L128), 
CD45RO (UCHL-1), CD103 (Ber-ACT8) from BD Pharmingen, San Diego, CA or 
Beckman Coulter, Brea, CA. FACSCanto II flow cytometer and FACSDiva software 
(BD Bioscience, San Jose, CA) were used. For each sample, negative controls were 
stained with irrelevant Abs conjugated with the same fluorochrome. The ‘‘fluorescence-
minus-one’’ (FMO) controls have also been used to define precisely the cells that have 
fluorescence above background levels. Briefly, the samples have been stained with all 
of the reagents except one. 
§ Preparation and characterization of porous scaffolds   
3D porous scaffolds were developed by adapting the phase inversion and salt leaching 
technique. Scaffold morphology was preliminary investigated via FESEM Microscopy 
(Quanta FEG200, FEI). Specimens were fractured using a razor blade along preferential 
directions, parallel and perpendicular to the surface. Transverse and longitudinal 
sections were covered by a thin chromium layer (ca. 20 nm) by automatic sputtering 
(Emitech K575X) to afford a more efficient electron conductivity of the scaffold 
surface.  The porosity was assessed in terms of pore size, shape and spatial distribution 
by images at different magnifications and fixed working distance (WD=10 mm).  To 
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obtain a quantitative estimation of the scaffold porosity, three different methods were 
used: weight measurements by gravimetric method (GM), 2D image analysis (2D-IA) 
and mercury intrusion porosimetry (MIP). The porosity was obtained by theoretical 
conditions.  The 2D-IA evaluation of porosity features (porosity degree, pore size and 
spatial distribution) was performed by a dedicated software (ImageJ 1.38b; NIH 
Freeware; National Institutes of Health, Bethesda).  The porosity degree was evaluated 
from the total surface area of counted pores whereas the pore sizes were derived.  
Means and standard deviations of pore fraction and size were determined on 10 
different SEM images. Porosity measurements by MIP were assessed to estimate the 
really interconnected pores and their specific pore surface.  A mercury surface tension 
of 480 mN/m and a contact angle of 141.38° were used, while a pressure gradient from 
400 Pa up to 200 KPa was intruded to exactly count either micro and macropores 
according to the Washburn equation.   
§ Scanning Electron Microscopy (SEM)  
As for the investigation of biohybrid scaffold, cells were fixed for 2 h in 2,5% 
glutaraldehyde solution and dehydrated with sequential washes in 50%, 70%, 80%, 90% 
and 100% ethanol. The samples were air-dried overnight before the chromium 
sputtering.  In this case, the accelerating voltage of the FESEM equipment (Quanta 
FEG200, FEI) was set at 5 kV, reducing the vacuum level into the chamber (LV or Low 
Vacuum mode), so preventing any negative interaction of electron beam with the 
cellular bodies. 
§ Cytogenetic analysis 
Karyotype was performed by standard GTG banding at 550 bands resolution (ISCN 
2009). Array-CGH was performed with a 44 K whole-genome oligonucleotide 
microarray Agilent Technologies (Santa Clara, CA) following the manufacturer 
protocol. Array data were visualized using the Genome Workbench standard edition 
ver. 5.0 Agilent Technologies (Santa Clara, CA) and compared with the human genome 
reference sequence hg19 (Feb. 2009). 
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
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§ Statistical analysis 
Microsoft Excel and MedCalc were used for data analysis. The correlations between 
gene expression was obtained using the Pearson’s correlation. All measurements were 
expressed as the mean + SE. A value of p< 0.05 values was considered statistically 
significant. 
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
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SUMMARY 
The immune system is an interactive network, including lymphoid organs, cells, 
humoral factors, and cytokines, which works synergistically in host defense from 
pathogens, such as viruses, bacteria, fungi, and parasites, and other foreign molecules.  
A disruption of this orchestrated process leads immunedeficiencies, allergy, 
autoimmune disease and tumors (3). 
 Primary immunodeficiencies (PIDs) are genetic disorders causing severe defects 
in different components of immune system. Nowadays, more than 200 well 
characterized genetic immunedeficiencies have been identified thanks to the advances in 
molecular genetics and immunology. PIDs are classified according to the component of 
the immune system that is primarily involved, including T, B, natural killer (NK) cells, 
phagocytic cells, and complement proteins. Within PIDs, the Severe combined 
immunodeficiency diseases (SCIDs) represent a spectrum of illnesses with similar 
clinical manifestations, which can be divided into several categories on the basis of the 
presence or absence of T cells, B cells and Natural Killer (NK) cells.  These are 
relatively rare diseases, collectively occurring in 1:100.000 live births. 
In this context, my PhD program has been focused to the study of some Immunological 
disorders, in order to identify “New Scenarios in Pathogenesis and Therapeutic 
Approaches”.  
Particularly, my research has been focused in the study functional role of 
FOXN1 transcription factor in the T-cell ontogeny, through the new strategy to develop 
an in vitro thymic organoid and  the setting-up of the first phase of in vitro models 
generation to study this transcription factor by using reprogramming technology. 



Moreover, my research effort has been devoted to characterization of the  role of 
c in cell cycle progression and survival of continuous and primary human malignant 
cell line, clarifying its involvement in leukemogenesis and the molecular mechanism by 
which this protein promotes tumor growth.  
In addition, I gave a contribution to better define the mechanisms underlying the 
pathogenesis of forms of immunedeficiencies leading autoimmunity and cancer, 
respectively APECED and A-T. 
Eventually, I participated to description of new clinical phenotype and novel 
genetic syndrome involving the immune system, opening new scenarios in the 
molecular mechanisms underlying the immune response. 
These results obtained during my PhD program could be useful both in the clinical 
practice and in the basic research of immunedysregulation.   
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1. APPLICATIONS TO GRANT PROPOSALS
(Dr Rosa Romano) 
1. SIRPED - Società Italiana di Ricerca Pediatrica 2011, with a project entitled: 
“Modulation of molecular mechanism implicated in the high predisposition to infection 
and cancer in children with Ataxia-Teleangiectasia”. 
2. PRIN - Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale - Call for 
MIUR Application 2010-11, with a project entitled: “Sviluppo di approcci innovativi 
diagnostici e terapeutici per le immunodeficienze primitive”. 
3. Futuro in Ricerca - Call for MIUR Application 2012, with a project entitled: “Study 
of the mechanisms that regulate B and T cell homeostasis in Primary 
Immunodefiencies: primary T cell defects and Common Variable Immunodeficiency 
(CVID)as models”. 
4. PRIN - Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale - Call for 
MIUR Application 2012, with a project entitled: “Sviluppo di approcci innovativi 
diagnostici e terapeutici per le immunodeficienze primitive”. 
5. Futuro in Ricerca - Call for MIUR Application 2013, with a project entitled: 
“Characterization of the potential oncogenic role of c by exploring its modulatory 
activity on genes related to growth signaling, cell cycle control and survival, and 
through its post-transcriptional miRNAs-mediated regulation”. 
6. Telethon Grant Proposals - Call for Applications 2010, with a project entitled:  
“Evaluation of the cytoplasmic role of ATM kinase in the autophagy-lysosomal 
pathway and its pathogenic implication in Ataxia Telangiectasia: potential modulatory 
effect of Betamethasone”. 
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2. SCIENTIFIC PRODUCTION 
(Dr Rosa Romano) 
LIST OF PUBLICATIONS 
1. Romano R., Palamaro L., Fusco A., Iannace L., Maio S., Vigliano I., Giardino 
G., Pignata C. From murine to human Nude/SCID: the thymus, T-cell development and 
the missing link. Clin Dev Immunol. 2012:467101, 2012. 
2. Vigliano I., Palamaro L., Bianchino G., Fusco A., Vitiello L., Grieco V., 
Romano R., Salvatore M., Pignata C.  Role of the common  chain in cell cycle 
progression of human malignant cell lines. Int Immunol. 24:159-167, 2012. 
3. Palamaro L., Vigliano I., Giardino G., Cirillo E., Aloj G., Romano R., Pignata 
C. SCID-like phenotype associated with an inhibitory autoreactive immunoglobulin. J 
Investig Allergol Clin Immunol. 22:67-70, 2012. 
4. Cirillo E., Romano R., Romano A., Giardino G., Durandy A., Nitsch L., 
Genesio R., Di Gregorio E., Cavalieri S., Abate G., Del Vecchio L., Brusco A., Pignata 
C. De novo 13q12.3q14.11 deletion involving BRCA2 gene in a patient with 
developmental delay,  elevated IgM levels, transient ataxia and cerebellar hypoplasia, 
mimicking an A-T like phenotype. Am J Med Genet. 158 A:2571-76, 2012. 
5. Palamaro L., Giardino G., Santamaria F., Romano R., Fusco A., Montella S., 
Salerno M., Ursini M.V., Pignata C. Interleukin 12 receptor deficiency in a child with 
recurrent bronchopneumonia and very high IgE levels. Ital J Pediatr. 38:46, 2012. 
6. Capalbo D., Giardino G., De Martino L., Palamaro L., Romano R., Gallo V., 
Cirillo E., Salerno M., Pignata C. Genetic basis of altered central tolerance and 
autoimmune diseases: a lesson from AIRE mutations. Int Rev Immunol. 31:344-62, 
2012. 
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7. Giardino G., Fusco A., Romano R., Gallo V., Maio F., Esposito T., Palamaro 
L., Parenti G., Salerno M.C., Vajro P., Pignata C. Betamethasone therapy in Ataxia-
Telangiectasia: unraveling the rationale of this serendipitous observation on the basis of 
the pathogenesis. Eur J Neurol. 20:740-47, 2013. 
8. Gallo V., Giardino G., Capalbo D., Palamaro L., Romano R., Santamaria F., 
Maio F., Salerno M., Vajro P., Pignata C. Alterations of the autoimmune regulator 
transcription factor and failure of central tolerance: APECED as a model.  Expert Rev 
Clin Immunol. 9:43-51, 2013. 
9. van de Vosse E., van Dissel J.T., Palamaro L., Giardino G., Santamaria F., 
Romano R., Fusco A., Montella S., Salerno M., Ursini M.V., Pignata C. The R156H 
variation in IL-12Rbeta1 is not a mutation. Ital J Pediatr. 39:12, 2013. 
10. Romano R., Palamaro L., Parenti G., Salerno M., Fusco A., Vajro P., Capalbo 
D., Ranieri B., Naddei R., Pignata C. Networking between c and GH-R signaling in the 
control of cell growth. Curr Signal Transduct Ther. 8:67-73, 2013. 
11. Palamaro L., Guarino V., Scalia G., Antonini D., De Falco L., Bianchino G., 
Fusco A., Romano R., Grieco V., Missero C., Del Vecchio L., Ambrosio L., Pignata C. 
Human skin-derived keratinocytes and fibroblasts co-cultured on 3D poly -
caprolactone scaffold support in vitro HSCs differentiation into T-lineage committed 
cells. Int Immunol. 25:703-14, 2013. 
12. Romano R., Palamaro L., Fusco A., Giardino G., Gallo V., Del Vecchio L., 
Pignata C. FOXN1: a master regulator gene of thymic epithelial development 
programme. Front Immunol. 2013 doi: 10.3389/fimmu.2013.00187. 
13. Fusco A., Panico L., Gorrese M., Bianchino G., Barone MV., Grieco V., Vitiello 
L., D’Assante R., Romano R., Palamaro L., Scalia G., Del Vecchio L., Pignata C. 


Molecular Evidence for a Thymus-Independent Partial T Cell Development in a 
FOXN1(-/-) Athymic Human Fetus. PLoS One.  8:e81786, 2013.
14. Palamaro L., Romano R., Fusco A., Giardino G., Gallo G., Pignata C. FOXN1 
in cell development and human diseases.   Int Rev Immunol. In press, 2014. 
15. Pignata C. and Romano R. In this issue: FOX genes and the immune response.   
Int Rev Immunol. In press, 2014.  
MEETING ABSTRACTS 
1. Palamaro L., Guarino V., Scalia G., Antonini D., De Falco L., Bianchino G., 
Fusco A., Romano R., Grieco V., Missero C., Del Vecchio L., Ambrosio L., Pignata C. 
Molecular signature if the T-cell commitment in an in vitro three-dimentional organoid 
mimicking the thymic microenvironment. 15
th
 Biennial Meeting of the European 
Society for Immunedeficiencies, Florence 3-6 October, 2012. J Clin Immunol. 32:310, 
2012 (Poster). 
2. Romano R., Ferrentino R., Pane L.S., Palamaro L., Fusco A., Marques J.G., 
Sousa A.B., de Sousa A.E., Ursini M.V., Baldini A., Pignata C. Preliminary steps of 
fibroblasts reprogramming to develop mTECs from control or FOXN1
-/-
 fibroblasts. 15
th
Biennial Meeting of the European Society for Immunedeficiencies, Florence 3-6 
October, 2012. J Clin Immunol. 32:332, 2012  (Poster). 
3. Cirillo E., Romano R., Giardino G., Anne D., Maio F., Gallo V., Di Gregorio 
E., Cavalieri S., Abate G. Del Vecchio L., Brusco A., Pignata C. Elevated IgM levels in 
a patient with de novo 13q12.3q14.11 deletion , mimicking an A-T like phenotype. 15
th
Biennial Meeting of the European Society for Immunedeficiencies, Florence 3-6 
October, 2012. J Clin Immunol. 32:211-212, 2012 (Poster). 
